



**HAL**  
open science

## **I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease**

Laurent Peyrin-Biroulet, Jean-François Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier Gisbert, Peter Bossuyt, Ulf Helwig, et al.

► **To cite this version:**

Laurent Peyrin-Biroulet, Jean-François Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, et al.. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, 2023, 21 (3), pp.771-788.e10. 10.1016/j.cgh.2022.09.018 . hal-04166331

**HAL Id: hal-04166331**

**<https://hal.univ-lorraine.fr/hal-04166331v1>**

Submitted on 10 Jan 2025


**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Journal Pre-proof

I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease

Laurent Peyrin-Biroulet, Jean-François Rahier, Julien Kirchgesner, Vered Abitbol, Shaji Sebastian, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamás Molnar, Mark Löwenberg, Jonas Halfvarson, Edyta Zagorowicz, Hélène Rousseau, Cédric Baumann, Filip Baert, Laurent Beaugerie, for the I-CARE Collaborator Group



PII: S1542-3565(22)00916-8  
DOI: <https://doi.org/10.1016/j.cgh.2022.09.018>  
Reference: YJCGH 58676

To appear in: *Clinical Gastroenterology and Hepatology*  
Accepted Date: 8 September 2022

Please cite this article as: Peyrin-Biroulet L, Rahier J-F, Kirchgesner J, Abitbol V, Sebastian S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L, for the I-CARE Collaborator Group, I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease, *Clinical Gastroenterology and Hepatology* (2022), doi: <https://doi.org/10.1016/j.cgh.2022.09.018>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 by the AGA Institute

# **I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease**

Short title: Safety and effectiveness of biologics in IBD

Laurent Peyrin-Biroulet<sup>1</sup>, Jean-François Rahier<sup>2</sup>, Julien Kirchgesner<sup>3</sup>, Vered Abitbol<sup>4</sup>, Shaji Sebastian<sup>5</sup>, Alessandro Armuzzi<sup>6</sup>, Konstantinos Karmiris<sup>7</sup>, Javier P. Gisbert<sup>8</sup>, Peter Bossuyt<sup>9</sup>, Ulf Helwig<sup>10</sup>, Johan Burisch<sup>11,12</sup>, Henit Yanai<sup>13</sup>, Glen A. Doherty<sup>14</sup>, Fernando Magro<sup>15</sup>, Tamás Molnar<sup>16</sup>, Mark Löwenberg<sup>17</sup>, Jonas Halfvarson<sup>18</sup>, Edyta Zagorowicz<sup>19</sup>, Hélène Rousseau<sup>20</sup>, Cédric Baumann<sup>20</sup>, Filip Baert<sup>21</sup>, and Laurent Beaugerie<sup>3</sup> for the I-CARE Collaborator Group\*

<sup>1</sup>University of Lorraine, Nancy University Hospital, Department of Gastroenterology, F-54000 Nancy, France and University of Lorraine, Inserm, NGERE, F-54000 Nancy, France

<sup>2</sup>Department of Gastroenterology and Hepatology, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium

<sup>3</sup>Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France

<sup>4</sup>Hopital Cochin AP-HP, Université Paris Cité, Paris, France

<sup>5</sup>Hull University Teaching Hospitals, Hull York Medical School/ University of Hull, Hull, UK

<sup>6</sup> Research Hospital, Rozzano - Department of Biomedical Sciences Humanitas University, Pieve Emanuele, Milan, Italy

<sup>7</sup>Venizeleio General Hospital, Heraklion, Greece

<sup>8</sup>Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad Autónoma de Madrid (UAM), Madrid\_Spain

<sup>9</sup>Imelda GI clinical research center, Imelda General Hospital, Bonheiden, Belgium

<sup>10</sup> Private Practice for Internal Medicine and University of Kiel, Germany

<sup>11</sup>Gastrounit, medical division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark

<sup>12</sup> Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark

<sup>13</sup> IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

<sup>14</sup> St. Vincent's University Hospital & University College Dublin, Ireland and INITiative IBD research network ([www.initiativeibd.ie](http://www.initiativeibd.ie))

<sup>15</sup>Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal

<sup>16</sup>Albert Szent-Györgyi Health center - Department of Internal Medicine, University of Szeged, Szeged, Hungary

<sup>17</sup>Amsterdam University Medical Center, location AMC Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

<sup>18</sup>Department. of Gastroenterology, Faculty of Medicine and Health, Örebro University, SE 70185 Örebro, Sweden

<sup>19</sup>The Maria Skłodowska-Curie National Research Institute of Oncology, Department of Oncological Gastroenterology, Warsaw, Poland

<sup>20</sup>Unit of methodology, data management and statistic, Nancy University Hospital, Vandoeuvre-lès-Nancy, France

<sup>21</sup>AZ Delta Hospital, Roeselare, Belgium.

**Corresponding author:**

Prof. Laurent Peyrin-Biroulet, MD, PhD

Inserm NGERE U1256 and Department of Gastroenterology

Nancy University Hospital, University of Lorraine

1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France

Tel: (+33) 383153661 Fax: (+33) 383153633

E-mail: [peyrinbiroulet@gmail.com](mailto:peyrinbiroulet@gmail.com)

Word count: 3106

References: 20

Figure and table: 5 tables and 1 figure

**Abbreviations:** 5-ASA (5-aminosalicylates), BCG (Bacille Calmette-Guerin), BMI (body mass index), CD (Crohn's disease), CDAI (Clinical Disease Activity Index), CESAME (Cancers Et Surrisque Associé aux Maladies inflammatoires intestinale en France), ECCO (European Crohn's and Colitis Organisation), eCRF (electronic case report form), EFFCA (European Federation of Crohn's and Ulcerative Colitis Associations), GETAID (Groupe d'Etude des Affections Inflammatoires du Tube Digestif), IBD (Inflammatory bowel disease), IBDu (Inflammatory Bowel Disease, unclassified), I-CARE (IBD Cancer and serious infections in Europe), IRB (institutional review board), PRO (patient reported outcomes), TNF (tumor necrosis factor), UC (ulcerative colitis)

### Data availability statement

The data underlying this article are available in the article.

### Conflict of interest

Laurent Peyrin-Biroulet - personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boehringer Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Entera, Theravance; Pandion Therapeutics - grants from Abbvie, MSD, Takeda, Fresenius Kabi - stock options: CTMA.

Rahier Jean-François reports: Speaker fee: Abbvie, MSD, Takeda, Pfizer, Ferring, Falk, Biogen, Amgen, Celltrion. Consultancy: Abbvie, Takeda, Hospira, Mundipharma, MSD, Pfizer, GlaxoSK, Janssen, Celltrion. Research grant: Takeda, Abbvie.

Julien Kirchgesner reports: consulting fees from Roche, Pfizer, Gilead; research support from Abbvie.

Vered Abitbol: speaker fee: Takeda, Amgen, Mylan Viatrix, Sandoz, Janssen, Fresenius, Gilead, Tillotts, Galapagos, Pfizer Consultancy: Celltrion, Takeda, Amgen, Mylan Viatrix, Sandoz, Janssen, Fresenius, Gilead, Tillotts, Galapagos, Pfizer

Shaji Sebastian holds research grants from Biogen, Takeda, AbbVie, Tillotts Pharma, Ferring and Biohit; served on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene and

Tillots Pharma; and has received speaker fees from AbbVie, Biogen, AbbVie, Janssen, Merck, Warner Chilcott and Falk Pharma

Alessandro Armuzzi reports consultant fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist, Roche, Samsung Bioepis, Sandoz, Takeda; lecture fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix; research grants: MSD, Takeda, Pfizer, Biogen

Konstantinos Karmiris has received personal fees from Abbvie, Amgen, Enorasis, Ferring, Galenica, Genesis, Janssen, MSD, Pfizer, Takeda, Vianex

Javier P. Gisbert has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma

Peter Bossuyt has received financial support for research from Abbvie, Amgen, Celltrion, Mylan, Pfizer and Takeda; lecture fees from AbbVie, Celltrion, Janssen, Lilly and Takeda; advisory board fees from Abbvie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros.

Ulf Helwig has received Lecture/Advisory board honoraria from: MSD; Abbvie, Falk Foundation, Takeda, Mundipharma, Hospira, Ferring, Vifor, Mylan, Janssen, Pfizer, Celltrion, Galapagos, BMS, Fresenius.

Johan Burisch has served as speaker, consultant, and advisory member for or has received research funding from MSD, AbbVie, Pfizer, Takeda, Janssen, Celgene, Bristol Myers, Galapagos, Ferring, Tillotts Pharma, Pharmacosmos, Vifor Pharma and Novo Nordisk

Henit Yanai reports institutional research grants from Pfizer; consulting fees from Abbvie, Ferring, Janssen, Neopharm Ltd., Pfizer, Takeda; honoraria for lectures from Abbvie, Janssen, Pfizer, Takeda; participation on a Data Safety Monitoring Board or Advisory Board from Abbvie, Neopharm Ltd., Pfizer, Takeda.

Glen Doherty Research Grants/Unrestricted Educational Grants: Abbvie, MSD, Pfizer, Janssen, Takeda, Tillotts, Amgen, Falk, Celltrion, Genuity Ireland, Abbott

Fees for speaking or consulting/advisory boards:|Abbvie, MSD, Pfizer, Janssen, Takeda/Shire, Tillotts, Falk, Amgen, Mylan, Celltrion, Gilead, Galapagos, BMS, Olympus

Fernando Magro has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Biogen, Takeda, Janssen, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, , Otsuka Pharmaceutical, and Vifor Pharma.

Tamás Molnar has served as speaker and/or member of advisory board for: Abbvie, Bristol Myers Squibb, Celgene, Dr. Falk, Egis, Ferring Pharmaceuticals, Fresenius Kabi, Janssen-Cilag, MSD, Mundipharma, Nutricia, Pfizer, Phytotec, Takeda, Teva, Sandoz, Vifor Pharma. He has received research grants from AbbVie, Pfizer, Takeda, Vifor Pharma

Mark Löwenberg has served as speaker and/or principal investigator for: Abbvie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos,



Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Dr Falk, Achmea healthcare, Galapagos and ZonMW.

Jonas Halfvarson as received personal fees as speaker, consultant and/or advisory board member for AbbVie, Aqilion AB, Celgene, Celltrion, Dr. Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, MSD, Novartis, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and has received grant support from Janssen, MSD, and Takeda, outside of the submitted work

Edyta Zagorowicz has received speaker fees from Janssen, Sandoz, Pfizer and Takeda, consulting fees from Takeda, Janssen, Sandoz, Ferring and BMS.

Hélène Rousseau: none

Cédric Baumann: speaker fee : TAKEDA

Filip Baert: Consultant and/or speaker: AbbVie, Arena, Celltrion, Falk, Ferring, Janssen, Mundipharma, MSD, Pfizer, Sandoz, Takeda, Vifor; research grants: from AbbVie, Amgen, Chiesi, Ipsen, Janssen, MSD.

Laurent Beaugerie received consulting fees from BMS, Janssen, Nordic Pharma and Mylan; lecture fees from Abbvie, BMS, Janssen, MSD, Ferring, and Takeda; research support from Abbvie, Celltrion, Ferring Pharmaceuticals, Hospira-Pfizer, Janssen, MSD, Mylan, Takeda and Tillots.

### **Authors' Contributions**

LPB and LB conceived the study. LPB wrote the article, and created tables and figure. JFR, JK, VA, SS, AA, KK, JG, PB, UH, JB, HY, GD, FM, TM, ML, JH, EZ, HR, CB, FB, and LB critically reviewed the content of the paper and supervised the project. All authors approved the final manuscript.

### **Funding**

This work was supported by following partners: Abbvie; Amgen; Ferring; Pfizer; Janssen; MSD; Takeda.

\*Contributors of the I-CARE Collaborator group are listed in the Appendix.

## Abstract

**Background and Aims:** There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with for anti-tumor necrosis factor and other biologics monotherapy as well as in combination with immunomodulators.

**Methods:** I-CARE was designed as a European prospective longitudinal observational multicenter cohort study, to include patients with a diagnosis of Crohn's disease, ulcerative colitis or IBD unclassified established at least 3 months prior to enrollment.

**Results:** A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6,169 (60.4%) patients with Crohn's disease, 3,853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving AZA/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one quarter of patients (26.8%) underwent prior IBD related surgery. Sixty-six % of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion, and 1.1% had a history of colonic, esophageal or uterine cervix high-grade dysplasia.

**Conclusion:** I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients.

Keywords: inflammatory bowel disease, biologics, safety, efficacy, I-CARE, cancer, lymphoma

Journal Pre-proof

## Why I-CARE?

Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are lifelong, disabling, and incurable chronic inflammatory disorders involving the gastrointestinal tract<sup>1,2</sup>. Over the last decades, biologic therapies have revolutionized the treatment of IBD<sup>3,4</sup>. Precise and individual long-term safety profiles (malignancy, infections) of biologicals, as monotherapy or in combination with immunomodulators are poorly studied.

While the efficacy of immunomodulators in treating IBD was first reported in the 1960s<sup>5</sup>, the CESAME (Cancers Et Surrisque Associé aux Maladies inflammatoires intestinales en France) study evaluating the risk of lymphoproliferative disorders in patients receiving thiopurines for IBD was published 50 years later<sup>6</sup>. CESAME was the first nationwide prospective observational cohort which was designed to assess the possible excess risk of cancer in patients with IBD receiving thiopurines<sup>6</sup>. The CESAME cohort study demonstrated that a large cross-sectional observational cohort is able to address accurately and rapidly the long-term major safety issues associated with the prolonged use of thiopurines, with an immediate impact on guidelines<sup>6-8</sup>. Given the incidence of individual malignancies such as lymphomas or colorectal cancer in the general population with the same age-distribution as seen in IBD patients (one case for 1000 patient-years or below), a minimal number follow-up time of 30,000 patient-years is necessary to statistically demonstrate a significant excess risk of cancer associated with exposure to any drug<sup>9-11</sup>. Clinical trials, meta-analyses and safety-dedicated registries, such as TREAT<sup>12</sup> and ENCORE<sup>13</sup> are underpowered to evaluate the impact of IBD therapies on the individual risk of cancer. Of note, IBD phenotype and disease activity may also impact cancer risk. This is well established for colorectal cancer<sup>9</sup> and might be similar for lymphomas. Some nationwide administrative health databases are adequately powered for demonstrating the statistical link between drug exposure and individual cancers<sup>10</sup>, but a proper adjustment for

IBD phenotype and disease activity is not possible due to the lack of corresponding data in these studies. Only large statistically powered prospective observational cohort studies with a standardized longitudinal follow-up, including a robust characterization of disease phenotype and a prospective follow-up of IBD activity can evidence based assess the risk-benefit ratio of current therapeutic strategies in the biologic era.

Achieving and maintaining endoscopic remission, prevention of bowel damage and reduction of IBD-related surgeries and hospitalizations have emerged as treatment goals in IBD patients<sup>14,15</sup>. The impact of anti-tumor necrosis factor (TNF) on the natural history of IBD (endoscopic remission, bowel damage, surgeries, and hospitalizations) beyond one year is unknown. The impact of anti-TNF therapy on long-term outcomes cannot be accurately studied using available clinical trial and registry databases. In order to properly assess the risk/benefit ratio of current therapeutic strategies, it was necessary to include all life-threatening events both IBD-related and non-IBD related by collecting all hospitalization reports in these patients.

Real-world data coming from a very large cohort of IBD patients with a long-term follow-up are needed to address these issues<sup>16</sup>. Same duration of follow-up across included patients (as well as a low number of dropout are required to ensure the accuracy of the data. The I-CARE (IBD Cancer and serious infections in Europe) project was initiated in 2010 by capitalizing on the experience of the CESAME cohort study. Limitations of the CESAME study included the lack of information on the dose and duration of treatments exposure as well as no prospective assessment of disease activity and severity. The objective of I-CARE was to assess prospectively the presence and the extent of safety concerns anti-TNF or other biologic agents alone or in combination with thiopurines among IBD patients. In addition, I-CARE represents a unique opportunity to investigate the potential for disease modification as well as health economics assessment. These real-world datas will be used to guide clinicians as well as healthcare Authorities and payers to provide the best care for IBD patients by optimizing

available therapies. These findings may assist in maximizing benefits and minimizing risks among IBD patients who are candidates for biological therapy.

Journal Pre-proof

## Methods

### *Study design*

I-CARE is a European prospective longitudinal observational multicenter cohort study. A total of 15 countries participated: Belgium, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, The Netherlands, Poland, Portugal, Spain, Sweden, and United Kingdom. All investigators are European gastroenterologists participating in the study on a voluntary basis. This project is centralized, sponsored, and coordinated by the GETAID (Groupe d'Etude des Affections Inflammatoires du Tube Digestif), and supported by ECCO (European Crohn's and Colitis Organisation) and EFFCA (European Federation of Crohn's and Ulcerative Colitis Associations).

Patient  $\geq 18$  years with an established diagnosis of CD, UC, or IBD unclassified (UBDu) since  $\geq 3$  months were included. The diagnosis of IBD was based on internationally accepted endoscopic, radiological, and/or histological criteria. After obtaining an informed consent, information about personal details (mobile and home phone number, email address) was recorded and the patient informed about how record data, using his/her private mobile, computer or other electronic device during the study period. Exclusion criteria were patients unable or refusing to sign the informed consent form, or with no regular access to internet, or receiving treatment at entry in the study with an immunomodulator other than thiopurines and methotrexate (e.g. cyclosporine, tacrolimus, mycophenolate mofetil), and those currently or previously enrolled in a randomized clinical trial (if the investigational product received was blinded, and if the treatment is unknown at time of enrollment in I-CARE).

Each investigator could enroll up to 130 patients (not mandatory) who were divided into 6 pre-defined groups at inclusion based on ongoing IBD-related treatment at inclusion; Group 1: patients without IBD-related treatment or treated with any 5-aminosalicylates (5-ASA) and/or



steroids formulations, Group 2: patients receiving thiopurines/methotrexate alone, Group 3: patients treated with anti-TNF therapy monotherapy (without any concomitant immunosuppressant), Group 4: patients treated with anti-TNF therapy in combination with thiopurines or methotrexate, Group 5: patients treated with vedolizumab with or without any concomitant medications, Group 6: patients treated with ustekinumab with or without any concomitant medications.

The primary objective of I-CARE is to assess prospectively the presence and the extent of safety concerns (cancers (especially lymphoma) and serious infections risks) for anti-TNF or other biologic alone or in combination with thiopurines among IBD patients. The safety profile of all steroid formulations is also analyzed. The four main secondary objectives of the I-CARE project are 1) to investigate prospectively the impact of anti-TNF or other biologic based strategies on the natural history of IBD and their potential for disease modification by collecting validated surrogate markers such as endoscopic remission and disease complications such as bowel damage (strictures, fistulas, abscess), surgeries, and hospitalizations, 2) to assess the evolution of PROs on a yearly basis and the impact of anti-TNF agents or other biologic on PROs in IBD, 3) to evaluate the benefit-risk ratio of strategies based on an earlier and wider use of anti-TNF or other biologic therapy for IBD, and 4) to assess the direct healthcare costs and cost-efficacy of current therapeutic strategies in IBD.

### *Data collection*

Each investigator selected and consented the patient, and entered the baseline demographic and disease characteristic data of the patient in the electronic case report form (eCRF). The gastroenterologist who completed the e-summary form was also requested every year to validate and, if necessary, correct the information prospectively entered by the patients on a

monthly basis. The gastroenterologist was also requested to evaluate yearly available endoscopic and imaging disease activity reports using a predefined and simplified scoring system.

A dedicated web-based tool was built by SANOIA, a service provider with experience in patient e-Diary and e-PRO to capture the information coming from the patients. SANOIA also ensured adequate reminder electronic messages to be sent to the patients for timely completion of the e-Diary and e-PRO. Patients completed the e-Diary on a monthly basis including e-PRO, hospitalizations, surgeries and cancer diagnosis. Lifestyle factors such as smoking status and alcohol consumption were recorded at enrollment. Patients who reported hospitalization were requested to provide the related hospitalization report. Patients who reported a cancer or a high-grade dysplasia were instructed to provide the related diagnostic pathology report. An alert system was set up to inform study coordinators and project managers of incomplete data or report of hospitalization, surgery, infection or cancer diagnostic to allow timely tracking of the pertinent documents to upload on the Web Portal. All hospitalization reports collected were coded by a dedicated expert coding group using the ICD-10 classification. Details on the coding methodology will be provided in a separate paper.

As the implementation of the I-CARE project across Europe at the national level was anticipated to be challenging, due to differences in language, regulatory, and practical aspects, healthcare systems, and patients' journey, we gathered a core group of national coordinators (1-3 gastroenterologists per country). Their roles were to identify potential investigators, to disseminate information about logistics and scientific aspects of I-CARE, to translate all patients' documents and questionnaires in local language, to motivate investigators, to get institutional review board (IRB) approval, and to interact with study coordinators on a regular basis.

*Cohort size calculation*

Calculation of cohort size was made based on the primary objective of I-CARE. We estimated, based on the CESAME lymphoma incidence rates <sup>6</sup>, that a minimum of 47,000 patient-years was needed for the study to have a statistical power of 80% to detect a lymphoma hazard ratio of at least 3.5 in the groups of patients receiving thiopurines, either alone or in combination with anti-TNF, vedolizumab or ustekinumab, relative to patients not receiving thiopurines (i.e. receiving anti-TNF alone or no immunosuppressor).

Journal Pre-proof

## Results

### *Patient characteristics*

From March 2016 to April 2019, 13,262 patients gave informed consent to participate in this study. Among these patients, one was secondarily detected as not fulfilling eligibility criteria, 2150 did not confirm their participation by not activating the e-PRO digital system, 445 activated the e-PRO digital system but did not complete any e-PRO questionnaire, 434 completed only one-PRO questionnaire, thus generating no follow-up time, and 26 withdraw secondarily their consent to the use of their data. Ultimately, 10,206 patients were included in the I-CARE study by 508 investigators from 15 countries (Figure 1). Clinical characteristics of the patients are summarized in Table 1, Table 2, Supplementary table 1 and Supplementary table 2. Among the 10,206 patients, 6,169 (60.4%) had CD, 3,853 (37.8%) had UC, and 184 (1.8%) had IBDu. There was a female preponderance in the cohort (52.8%). The majority of patients had never smoked (54.8%). Mean body mass index (BMI) at inclusion was 24.8 (4.8) kg.m<sup>2</sup>. Approximately 75% of patients had a job, 6.8% were retired, and 9.2% were students.

A total of 1,141 (11.9%) patients had a family history of IBD (11.0% for UC and IBDu patients and 12.5% for CD patients,  $p=0.03$ ). Age at diagnosis of IBD was  $\leq 16$  years in 1,182 (11.6%) patients, between 17 and 40 years in 7,314 (71.7%) patients, and  $> 40$  years in 1,710 (16.8%) patients. Mean age at inclusion was 39.8 (13.1) years. Mean disease duration at inclusion was 10.6 (8.9) years (9.8 (8.5) years for UC and IBDu patients and 11.2 (9.1) years for CD patients,  $p<0.0001$ ). Location of disease at diagnosis according to Montreal classification was mainly ileocolonic in CD (42.9%), and extensive colitis in UC (45.5%). CD behavior at enrollment was inflammatory in 52% of the cases. Perianal disease was present in 27.9% of CD patients. One hundred and seventy-four (1.8%) had concomitant primary sclerosing cholangitis (2.3% of both the UC and IBDu patients, and 1.5% of the CD patients).

At inclusion about a quarter of patients (26.8%) underwent previous IBD-related surgery (41.7% of the CD patients, and 4.0% of the UC and IBDu patients,  $p<0.0001$ ). The most frequent surgical procedures were ileocecal resection in 24.4% (1,504/6,169) of CD patients, and perianal surgery in 13.9% (806/6,169) of CD patients.

#### *Prior and current medications*

IBD-related medications at study entry are summarized in Table 3 and Table 4. Previous treatments before inclusion are summarized in Supplementary table 3, Supplementary table 4, and Supplementary table 5.

#### 5-ASA/ mesalazine

A total of 3,413 (36.4%) patients received previous treatment with oral 5-ASA (mesalazine), and 2,229 (23.6%) with topical 5-ASA. The majority of patients who were previously treated with topical 5-ASA had UC or IBDu ( $p<0.0001$ ). At study entry, 3,568 (35%) were receiving oral 5-ASA, and 1,010 (9.9%) patients topical 5-ASA. They were more likely to suffer from UC ( $p<0.0001$ ).

#### Corticosteroids

A large majority of patients (65.9%) were previously treated with systemic steroids. Budesonide was previously used in 1,990 (21%) patients (7.2% in UC patients and 30.1% in CD patients,  $p<0.0001$ ), and budesonide MMX in 106 (1.1%) patients. At enrollment, 569 (5.6%) patients were receiving systemic corticosteroids (oral or intravenous). Budesonide was prescribed in 148 (1.5%) patients, and budesonide MMX in 28 patients (0.3%).

#### Immunosuppressants/ immunomodulators

30.7% (3136/10,206) of patients reported previous treatment with azathioprine, 6.3% (638/10,206) with methotrexate, and 4.7% (478/10,206) with 6-mercaptopurine. Among 30.7% of patients who received azathioprine prior to study entry, almost half of them (48.4%) were exposed for less than one year.

At enrollment, 3,294 (32.3%) patients were receiving thiopurines, 4.6% (468/10,206) 6-mercaptopurine, and 3.2% (325/10,206) methotrexate. Patients receiving azathioprine or methotrexate were more likely to have CD compared to patients not receiving methotrexate ( $p < 0.0001$ ).

### Biologics

A total of 1,690 (17.8%) patients had received infliximab before entering the study. Of the enrolled patients, 1,334 (14.0%) had prior use of adalimumab, 141 (1.5%) golimumab, and 60 (0.6%) certolizumab pegol. Concerning other biologics than anti-TNF, 147 (1.5%) had prior use of vedolizumab, and 38 (0.4%) ustekinumab.

At study entry, 2,725 (26.7%) patients were receiving infliximab, 1,937 (19%) adalimumab, 149 (1.5%) golimumab, 9 (0.1%) certolizumab pegol, 894 (8.8%) vedolizumab, and 343 (3.4%) ustekinumab.

### *History of cancer or dysplasia*

Among all included patients, 298 (2.9%) patients had a prior history of any-type of cancer, including 135 UC or IBDu and 163 CD patients, (Supplementary table 6). Moreover, 108 patients (1.1%) had a medical history of high-grade dysplasia: 20 patients had colonic high-grade dysplasia, 3 esophageal high-grade dysplasia, and 71 uterine cervix high-grade dysplasia. There was no difference between UC and CD patients. A total of 1,085 (11.3%) patients had a

family history (first degree relative) of any of the following cancer: lymphoma, colorectal cancer, melanoma or breast cancer (Supplementary table 1).

#### *History of vaccination and infection*

Vaccination rate was 6.2% for human papillomavirus vaccine, 56.5% for hepatitis B vaccine, 35.1% for pneumococcus vaccine, and 53.9% for Bacille Calmette-Guerin (BCG) vaccine (Supplementary table 7). A confirmed history of symptomatic mononucleosis infection was reported in 376 patients (5%), including 140 UC or IBDu, and 236 CD patients before inclusion.

## Discussion

I-CARE is the first prospective cohort study that is specifically designed to assess the risk-benefit ratio of current therapeutic strategies in the biologic era in patients with IBD. I-CARE is a European collaborative effort involving 15 countries. A total of 10,206 IBD patients were enrolled between March 2016 and April 2019.

To reach the I-CARE objectives, we developed innovative tools like a dedicated web-based tool to capture the information (e-Diary and e-PRO) coming from the patients, and a second platform to house the investigators database and eCRF completed by the investigators (Supplementary Figure 1). An interface was built between these two systems to allow enrollment of patients after the investigators completed their contact information on the eCRF, and investigators to have a summary of data entered by their patients for validation.

One of the strengths of the I-CARE project was the quality of data collection (Table 5). The patient had a central role in the investigation. However, patient data were annually reviewed and validated by their gastroenterologist. For cancer, dysplasia, any IBD related and IBD non-related hospitalizations, surgeries, the corresponding hospitalization and histological reports were collected. Collected comorbidities are alcohol, smoking, BMI. From the hospitalization reports, we will be able to collect other comorbidities, and perform a nested case control study.

The majority of patients had a CD diagnosis in ICARE (60.4%), this rate was similar to the CESAME study (60.3%)<sup>7</sup>. Age at diagnosis of IBD was similar to the previous study, with a large majority of patients diagnosed between 17 and 40 years of age<sup>17</sup>. Concerning the Montreal classification and the presence of perianal lesions, our data were consistent with literature<sup>18</sup>. As expected, in I-CARE, patients were more likely to be treated with biologics than in other databases<sup>19,20</sup>. Even though I-CARE is not a population-based study because of a large sample



size, baseline characteristics are those commonly observed in European studies underscoring its validity and representativeness<sup>19,20</sup>.

The primary focus of I-CARE was to address the lymphoma risk, including other malignancies, as well as serious infections in IBD patients exposed to biologics. Based on CESAME experience, to minimize potential bias and confounding effects for evaluation of the effect of each treatment exposure on the occurrence of severe infection, cancer and hospitalization, propensity score (using all details of IBD phenotype and history) for each treatment will be/ was calculated using logistic regression models. To overcome the main limitations of the CESAME project, we prospectively assessed clinical disease activity in IBD patients through prospective monthly assessments (HBI (Harvey-Bradshaw Index) for CD and SCCAI (Simple Clinical Colitis Activity Index) for UC), and disease activity/severity through a scoring system of imaging and endoscopic reports. To this end, we were able to adjust for IBD activity the relationship between drug exposures and outcomes. We also recorded and quantified the exposure to IBD drugs of interest from IBD diagnosis, prior to the enrollment into the cohort, in order to be able to address the potential link between the cumulative dose of drug exposure and the late occurrence of malignancies. For the first time, we have collected all IBD treatments received since IBD diagnosis (every course, every drug class, every date of start and duration of treatment). Only the precise dose was not collected before I-CARE entry. Finally, we recorded family histories of lymphoma, colorectal cancer, melanoma and breast cancer that have been shown to have a key role in the individual cancer risks. The statistical power and granularity of ICARE will provide unique information on the relationships between IBD drugs and efficacy and safety outcomes in the biologics era.

Regarding the obstacles encountered during the I-CARE project, it was necessary to convince countries with existing national cohort to participate in the I-CARE project, obtain regulatory approval across countries, develop authorship rules, organize regular meetings at international

conferences to inform and motivate collaborators, and define a precise task distribution given the number of people involved in this project.

Future findings from I-CARE and sub-studies will likely be implemented in IBD guidelines and used to guide the decision-making process in daily practice.

Journal Pre-proof

## Regulatory

Master ICARE Protocol received an approval from Saint Louis Ethic Committee on 15/05/2015 and CNIL approval on 27/10/2015.

Each country participating to ICARE had the responsibility to submit the protocol and the amendments in agreement with their own local regulation.

I-CARE Eudract Number : 2014-004728-23

Clinical Trial.gov – Register number : NCT 02377258

N° INDS : TP305083

CEREES approval on 20 Feb 2019

\*Members of the I-CARE collaborator group are listed in the Appendix.

## Acknowledgments

- We thank all the patients for their active participation in the project.
- We thank our partners: Abbvie; Amgen; Ferring; Pfizer; Janssen; MSD; Takeda.

## References

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. *Lancet*. 2017;389:1741-1755. doi:10.1016/S0140-6736(16)31711-1
2. Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. *Lancet*. 2012;380:1606-1619. doi:10.1016/S0140-6736(12)60150-0
3. De Felice KM. Patients Perception of Risks and Benefits of Biologic Therapy. *Inflammatory Bowel Diseases*. 2020;26:147-149. doi:10.1093/ibd/izz122
4. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet*. 2008;371:660-667. doi:10.1016/S0140-6736(08)60304-9
5. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. *Lancet*. 1969;2:612-614. doi:10.1016/s0140-6736(69)90325-0
6. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet*. 2009;374:1617-1625. doi:10.1016/S0140-6736(09)61302-7
7. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology*. 2011;141:1621-1628.e1-5. doi:10.1053/j.gastro.2011.06.050
8. Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. *J Crohns Colitis*. 2015;9:945-965. doi:10.1093/ecco-jcc/jjv141

9. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. *N Engl J Med*. 2015;372:1441-1452. doi:10.1056/NEJMra1403718
10. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. *JAMA*. 2017;318:1679-1686. doi:10.1001/jama.2017.16071
11. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor- $\alpha$  antagonists and risk of cancer in patients with inflammatory bowel disease. *JAMA*. 2014;311:2406-2413. doi:10.1001/jama.2014.5613
12. Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. *Inflamm Bowel Dis*. 2018;24:490-501. doi:10.1093/ibd/izx072
13. D'Haens G, Reinisch W, Colombel JF, et al. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. *J Crohns Colitis*. 2017;11:680-689. doi:10.1093/ecco-jcc/jjw221
14. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. *Curr Opin Gastroenterol*. 2013;29:397-404. doi:10.1097/MOG.0b013e3283622914
15. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-

- Target strategies in IBD. *Gastroenterology*. 2021;160:1570-1583. doi:10.1053/j.gastro.2020.12.031
16. Le Berre C, Peyrin-Biroulet L, SPIRIT-IOIBD study group. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. *Gastroenterology*. 2021;160:1452-1460.e21. doi:10.1053/j.gastro.2020.10.065
17. Duricova D, Burisch J, Jess T, et al. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. *Journal of Crohn's and Colitis*. 2014;8:1351-1361. doi:10.1016/j.crohns.2014.05.006
18. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*. 2011;140:1785-1794. doi:10.1053/j.gastro.2011.01.055
19. Burisch J, Katsanos KH, Christodoulou DK, et al. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. *J Crohns Colitis*. 2019;13:198-208. doi:10.1093/ecco-jcc/jjy154
20. Burisch J, Kiudelis G, Kupcinkas L, et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. *Gut*. 2019;68:423-433. doi:10.1136/gutjnl-2017-315568

## Figure legend

**Figure 1.** Patient's Flowchart

## Table legends

**Table 1.** Baseline characteristics

**Table 2.** Disease characteristics

**Table 3.** Ongoing immunomodulators, corticosteroids and 5-ASA treatments at entry

**Table 4.** Ongoing Biological treatments at entry

**Table 5.** Strengths of I-CARE

**Table 1. Baseline characteristics**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Distribution of patients included by country</b>										<.0001
Belgium	499	4.9		185	4.6		314	5.1		
Denmark	320	3.1		148	3.7		172	2.8		
France	2955	29.0		1007	24.9		1948	31.6		
Germany	481	4.7		208	5.2		273	4.4		
Greece	850	8.3		307	7.6		543	8.8		
Hungary	244	2.4		98	2.4		146	2.4		
Ireland	273	2.7		117	2.9		156	2.5		
Israel	298	2.9		75	1.9		223	3.6		
Italy	861	8.4		404	10.0		457	7.4		
Netherlands	116	1.1		45	1.1		71	1.2		
Poland	80	0.8		22	0.5		58	0.9		
Portugal	267	2.6		99	2.5		168	2.7		
Spain	791	7.8		312	7.7		479	7.8		
Sweden	94	0.9		63	1.6		31	0.5		
United Kingdom	2077	20.4		947	23.5		1130	18.3		
<b>Disease duration at inclusion (years)</b>	10206	10.6	8.9	4037	9.8	8.5	6169	11.2	9.1	<.0001
<b>Gender</b>										<.0001
Female	5385	52.8		2032	50.3		3353	54.4		
Male	4821	47.2		2005	49.7		2816	45.6		
<b>Age at inclusion (years)</b>	10206	39.8	13.1	4037	41.5	13.7	6169	38.7	12.5	<.0001
<b>IBD sub type</b>										<.0001
Crohn's Disease	6169	60.4		0	0.0		6169	100.0		
IBD Unclassified	184	1.8		184	4.6		0	0.0		
Ulcerative Colitis	3853	37.8		3853	95.4		0	0.0		
<b>Working status</b>										<.0001
Having a job	7644	74.9		3048	75.5		4596	74.5		
Unemployed	923	9.0		303	7.5		620	10.1		
Retired	698	6.8		337	8.3		361	5.9		
Student	941	9.2		349	8.6		592	9.6		
<b>Body Mass Index (kg.m<sup>2</sup>)</b>	9384	24.8	4.8	3728	25.0	4.7	5656	24.7	4.9	0.0001
<b>Smoking status</b>										<.0001
Current	1471	15.5		336	8.9		1135	19.8		
Former	2827	29.8		1199	31.8		1628	28.4		
Never	5204	54.8		2235	59.3		2969	51.8		
Missing	704			267			437			
<b>Alcohol Consumption</b>										<.0001
No	7715	81.0		2917	77.1		4798	83.6		
Yes	1805	19.0		864	22.9		941	16.4		
Missing	686			256			430			

\* Chi-square test for qualitative variables, Wilcoxon test for quantitative variables  
Abbreviation: IBD (Inflammatory Bowel Disease), SD (Standard Deviation)



**Table 2. Disease characteristics**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Age at diagnosis (years)</b>										<.0001
(A1) 16 and below	1182	11.6		325	8.1		857	13.9		
(A2) between 17 and 40 included	7314	71.7		2848	70.5		4466	72.4		
(A3) 41 and above	1710	16.8		864	21.4		846	13.7		
<b>CD Location (L1, L2, L3)</b>										
(L1) ileal, including caecum	2172	37.9					2172	37.9		
(L2) colonic	1100	19.2					1100	19.2		
(L3) ileocolonic	2463	42.9					2463	42.9		
Missing	434						434			
<b>CD Behavior (B1, B2, B3)</b>										
(B1) non-stricturing, non- penetrating	2976	52.0					2976	52.0		
(B2) stricturing	1613	28.2					1613	28.2		
(B3) penetrating	1134	19.8					1134	19.8		
Missing	446						446			
<b>Any perianal disease</b>										
No	4145	72.1					4145	72.1		
Yes	1606	27.9					1606	27.9		
Missing	418						418			
<b>UC involvement (E1, E2, E3)</b>										
(E1) Proctitis	551	14.6		551	14.6					
(E2) Left sided colitis	1501	39.9		1501	39.8					
(E3) Extensive UC	1714	45.5		1715	45.5					
Missing	271			271						
<b>Cumulative estimated microscopic and/or macroscopic extend of the surface of colonic mucosa</b>										<.0001
0%	2321	27.3		436	13.0		1885	36.8		
]0%-50%]	3210	37.8		1396	41.5		1814	35.4		
]50%-100%]	2961	34.9		1533	45.6		1428	27.9		
Missing	1714			672			1042			
<b>Associate confirmed primary sclerosing cholangitis</b>										0.0031
No	9262	98.2		3657	97.7		5605	98.5		
Yes	174	1.8		88	2.3		86	1.5		
Missing	770			292			478			

\* Chi-square test

Abbreviation : CD (Crohn's Disease), SD (Standard Deviation), UC (Ulcerative Colitis)

**Table 3. Ongoing immunomodulators, corticosteroids and 5-ASA treatments at entry**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Any oral form of 5-ASA (oral)</b>										<.0001
No	6638	65.0		1473	36.5		5165	83.7		
Yes	3568	35.0		2564	63.5		1004	16.3		
<b>Any topical forms of 5-ASA (suppository, foam, enema)</b>										<.0001
No	9196	90.1		3103	76.9		6093	98.8		
Yes	1010	9.9		934	23.1		76	1.2		
<b>Any form of systemic corticosteroids</b>										<.0001
No	9637	94.4		3721	92.2		5916	95.9		
Yes	569	5.6		316	7.8		253	4.1		
<b>Corticosteroids: administration of treatment</b>										0.1963
Intravenous	11	1.9		4	1.3		7	2.8		
Oral	558	98.1		312	98.7		246	97.2		
<b>Budesonide (oral)</b>										<.0001
No	10058	98.5		4018	99.5		6040	97.9		
Yes	148	1.5		19	0.5		129	2.1		
<b>Budesonide MMX (oral)</b>										<.0001
No	10178	99.7		4015	99.5		6163	99.9		
Yes	28	0.3		22	0.5		6	0.1		
<b>Beclometasone (oral)</b>										<.0001
No	10186	99.8		4019	99.6		6167	100.0		
Yes	20	0.2		18	0.4		1	0.0		
<b>Azathioprine</b>										<.0001
No	6912	67.7		2890	71.6		4022	65.2		
Yes	3294	32.3		1147	28.4		2147	34.8		
<b>6-Mercaptopurine</b>										0.2819
No	9738	95.4		3863	95.7		5875	95.2		
Yes	468	4.6		174	4.3		294	4.8		
<b>Methotrexate</b>										<.0001
No	9881	96.8		3969	98.3		5912	95.8		
Yes	325	3.2		68	1.7		257	4.2		

\* Chi-square test

Abbreviations : 5-ASA (5-aminosalicylates), SD (Standard Deviation)

**Table 4. Ongoing Biological treatments at entry**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Biological treatments</b>										<.0001
Adalimumab	1937	19.0		262	6.5		1675	27.2		
Certolizumab Pegol	9	0.1		1	0.0		8	0.1		
Golimumab	149	1.5		137	3.4		12	0.2		
Infliximab	2725	26.7		853	21.1		1872	30.3		
None	4149	40.6		2280	56.5		1869	30.3		
Ustekinumab	343	3.4		12	0.3		331	5.4		
Vedolizumab	894	8.8		492	12.2		402	6.5		
<b>Infliximab: Estimated duration of treatment before entry in I-CARE (years)</b>										
<1 year	780	28.6		303	35.5		477	25.5		
1 year	363	13.3		129	15.1		234	12.5		
2 years	353	13.0		117	13.7		236	12.6		
3 years	260	9.5		72	8.4		188	10.0		
4 years	217	8.0		66	7.7		151	8.1		
5 years	162	5.9		43	5.0		119	6.4		
6 years	143	5.2		36	4.2		107	5.7		
7 years	113	4.1		25	2.9		88	4.7		
8 years	80	2.9		22	2.6		58	3.1		
9 years	70	2.6		16	1.9		54	2.9		
10 years	56	2.1		10	1.2		46	2.5		
11 years	44	1.6		5	0.6		39	2.1		
12 years	32	1.2		3	0.4		29	1.5		
13 years	18	0.7		2	0.2		16	0.9		
14 years	10	0.4		2	0.2		8	0.4		
15 years	9	0.3		2	0.2		7	0.4		
16 years	9	0.3		0	0.0		9	0.5		
17 years	1	0.0		0	0.0		1	0.1		
18 years	1	0.0		0	0.0		1	0.1		
19 years	1	0.0		0	0.0		1	0.1		
20 years	1	0.0		0	0.0		1	0.1		
Missing	2			0			2			
<b>Adalimumab: Estimated duration of treatment before entry in I-CARE (years)</b>										
<1 year	564	29.1		109	41.6		455	27.2		
1 year	297	15.3		47	17.9		250	14.9		
2 years	319	16.5		40	15.3		279	16.7		
3 years	211	10.9		19	7.3		192	11.5		
4 years	183	9.4		21	8.0		162	9.7		
5 years	97	5.0		9	3.4		88	5.3		
6 years	81	4.2		6	2.3		75	4.5		
7 years	75	3.9		3	1.1		72	4.3		
8 years	41	2.1		4	1.5		37	2.2		
9 years	28	1.4		1	0.4		27	1.6		
10 years	24	1.2		3	1.1		21	1.3		
11 years	8	0.4		0	0.0		8	0.5		
12 years	2	0.1		0	0.0		2	0.1		
13 years	2	0.1		0	0.0		2	0.1		
14 years	1	0.1		0	0.0		1	0.1		
Missing	4			0			4			
<b>Certolizumab Pegol: Estimated duration of treatment before entry in I-CARE (years)</b>										
<1 year	2	22.2		1	100.0		1	12.5		0.6667
1 year	3	33.3		0	0.0		3	37.5		
2 years	1	11.1		0	0.0		1	12.5		
3 years	1	11.1		0	0.0		1	12.5		
4 years	1	11.1		0	0.0		1	12.5		
7 years	1	11.1		0	0.0		1	12.5		
<b>Golimumab: Estimated duration of treatment before entry in I-CARE (years)</b>										
<1 year	76	51.0		71	51.8		5	41.7		0.1842
1 year	36	24.2		34	24.8		2	16.7		

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
2 years	25	16.8		23	16.8		2	16.7		
3 years	10	6.7		7	5.1		3	25.0		
4 years	2	1.3		2	1.5		0	0.0		
<b>Vedolizumab: Estimated duration of treatment before entry in I-CARE (years)</b>										0.3220
<1 year	576	64.5		325	66.1		251	62.6		
1 year	187	20.9		93	18.9		94	23.4		
2 years	97	10.9		57	11.6		40	10.0		
3 years	24	2.7		11	2.2		13	3.2		
4 years	7	0.8		5	1.0		2	0.5		
5 years	1	0.1		1	0.2		0	0.0		
8 years	1	0.1		0	0.0		1	0.2		
Missing	1			0			1			
<b>Ustekinumab: Estimated duration of treatment before entry in I-CARE (years)</b>										0.0950
<1 year	237	69.1		10	83.3		227	68.6		
1 year	55	16.0		0	0.0		55	16.6		
2 years	36	10.5		0	0.0		36	10.9		
3 years	8	2.3		2	16.7		6	1.8		
4 years	2	0.6		0	0.0		2	0.6		
5 years	2	0.6		0	0.0		2	0.6		
6 years	1	0.3		0	0.0		1	0.3		
7 years	1	0.3		0	0.0		1	0.3		
8 years	1	0.3		0	0.0		1	0.3		

\* Chi-square test or Fisher's exact test  
Abbreviation : SD (Standard Deviation)

**Table 5. Strengths of I-CARE**

1. Large statistically powered prospective observational cohort study
2. Real-world data
3. Standardized longitudinal follow-up
4. Long-term follow-up
5. Quality of data collection
6. Primary objective: to assess prospectively the presence and the extent of safety concerns (cancers (especially lymphoma) and serious infections risks) for anti-TNF or other biologic alone or in combination with thiopurines
7. Secondary objectives: <ul style="list-style-type: none"> <li>- To investigate prospectively the impact of anti-TNF or other biologic based strategies on the natural history of IBD and their potential for disease modification</li> <li>- To assess the evolution of PROs on a yearly basis and the impact of anti-TNF agents or other biologic on PROs in IBD</li> <li>- To evaluate the benefit-risk ratio of strategies based on an earlier and wider use of anti-TNF or other biologic therapy for IBD</li> <li>- To assess the direct healthcare costs and cost-efficacy of current therapeutic strategies in IBD</li> </ul>




Figure 1 : Patient 's Flowchart

**Appendix: I-CARE Collaborator Group****Investigators, listed by decreasing number of patients enrolled:**

Jean-Marc GORNET, Hôpital Saint-Louis, Université Paris Nord, Paris, France; Laurent BEAUGERIE, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Sebastian SHAJI, Hull University Teaching Hospitals, Hull York Medical School - University of Hull, Hull, UK; Laurent PEYRIN-BIROULET, CHRU Nancy, Nancy University, Nancy, France; Jean-Marie REIMUND, Hôpital universitaire de Strasbourg, Université de Strasbourg, Strasbourg, France; Xavier HEBUTERNE, Hôpital L'archet, Nice, France; Aurélien AMIOT, Hôpital Henri Mondor Université Paris Est, Créteil, France; Franco ARMELAO, Ospedale Santa Chiara, Azienda Provinciale per i Servizi Sanitari, Trento, Italy; Pierre BLANC, CHU Montpellier, Université de Montpellier, Montpellier, France; Claudio PAPI, Ospedale San Filippo Neri, Roma, Italy; Guillaume PINETON DE CHAMBRUN, Hôpital Saint-Eloi, Université de Montpellier, Montpellier, France; Xavier ROBLIN, CHU Saint-Etienne, Saint-Etienne Université, Saint-Etienne, France; Konstantinos KARMIRIS, Venizeleio General Hospital, Heraklion, Greece; Sohail SHARIQ, Ealing Hospital, Imperial college london, London, UK; Nikolaos VIAZIS, Evangelismos General Hospital, Athens, Greece; Jimmy LIMDI, Northern Care Alliance NHS Foundation Trust, University of Manchester, Manchester, UK; Piotr EDER, H. Święcicki University Hospital, Poznan University of Medical Sciences, Poznan, Poland; Georgios MICHALOPOULOS, Tzaneion General Hospital, Pireaus, Greece; Andrew BELL, Weston General Hospital, Weston-Super-Mare, UK; Livia BIANCONE, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; Marie DEWITTE, CHU Rennes - Hôpital Pontchaillou, Université Rennes 1, Rennes, France; Zia MAZHAR, Basildon and Thurrock University Hospitals NHS Trust, Basildon, UK; Denis FRANCHIMONT, Erasmus Hospital, VUB -ULB, Brussels, Belgium; Stephane NANCEY, Hôpital Lyon-Sud, Université

Lyon 1, Lyon, France; Gilles MACAIGNE, CH Marne la vallée, Jossigny, France; Maria Beatrice PRINCIPI, Policlinico di Bari, Università di Bari, Bari, Italy; Mathurin FUMERY, CHU Amiens, Université de Picardie Jules Verne, Amiens, France; Gareth PARKES, St Bartholomew's Hospital, Queen Mary University of London, London, UK; Jean-Christophe VALATS, CHU Montpellier, Université de Montpellier, Montpellier, France;; Glen DOHERTY, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Guillaume BOUGUEN, CHU Rennes - Hôpital Pontchaillou, Université Rennes 1, Rennes, France; Tamás MOLNAR, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary;; Hersin TSAI, Hull University Teaching Hospitals, Hull York Medical School - University of Hull, Hull, UK; Mohsin GANGI, Stepping Hill Hospital, Stockport, UK; Natalia PEDERSEN, Slagelse Hospital, University of Copenhagen, Slagelse, Denmark; Frédéric HELUWAERT, CH Annecy Genevois, Annecy, France; Richard SHENDEREY, Airedale General Hospital, Leeds University School of Medicine, Airedale, UK; Sebastian ZEISSIG, , University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Jeffrey BUTTERWORTH, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Fabiana CASTIGLIONE, Policlinico Federico II, Università Federico II, Napoli, Italy; Lynsey CORLESS, Hull University Teaching Hospitals, Hull York Medical School- University of Hull, Hull, UK; Camille ZALLOT, CHRU Nancy, Université de Nancy, Nancy, France; ; Filip BAERT, AZ Delta, campus Rumbeke, Roeselare, Belgium; Salil SINGH, Royal Bolton Hospital, Bolton, UK; Sunil SONWALKAR, Calderdale Royal Hospital, Halifax, UK; Julie BURTON, Pinderfields Hospital, Wakefield, UK; Elizabeth CLAYTON, Pinderfields Hospital, Wakefield, UK; Jean-François RAHIER, CHU Namur, site Godinne, University of Namur, Namur, Belgium; Deven VANI, Pinderfields Hospital, Wakefield, UK; Renata D'INCA, Ospedale di Padova, Università di Padova, Padova, Italy; Guy BELLAICHE, Hôpital Robert Ballanger, Université de Bobigny, Aulnay-sous-bois,



France; Martine DE VOS, UZ Ghent, Ghent University, Ghent, Belgium; Julien KIRCHGESNER, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Uri KOPYLOV, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Triana LOBATON, UZ Ghent, Ghent University, Ghent, Belgium; Christophe LOCHER, Hôpital de Meaux, Meaux, France; Gerassimos MANTZARIS, Evangelismos General Hospital, Athens, Greece; George ABOUDA, Hull University Teaching Hospitals, Hull York Medical School - University of Hull, Hull, UK; Katie SMITH, Michael SPRAKES, Pinderfields Hospital, Wakefield, UK; Yeovil District Hospital, Yeovil, UK; Angeliki THEODOROPOULOU, Venizeleio General Hospital, Heraklion, Greece; Emma WESLEY, Musgrove Park Hospital, Taunton, UK; Joëlle BONNET, Hôpital Saint-Louis, Université Paris Nord, Paris, France; David ELPHICK, Chesterfield Royal Hospital, Chesterfield, UK; Cyrielle GILLETTA, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; John GORDON, Hampshire Hospitals, University of Southampton, Basingstoke, UK; David LAHARIE, CHU Bordeaux, Université de Bordeaux, Pessac, France; Antoine NAKAD, Chwapi Hospital, Tournai, Belgium; Ambrogio ORLANDO, Ospedale V. Cervello, Università di Palermo, Palermo, Italy; Patrick DUBOIS, Kings College Hospital, King's College London, London, UK; Peter HASSELBLATT, Universitätsklinikum Freiburg, Universitätsklinikum Freiburg, Freiburg, Germany; Christophe MICHIELS, CHU Dijon, Dijon, France; Cathryn PRESTON, Bradford Teaching Hospitals, Leeds School of Medicine, Bradford, UK; Anca STAICU, Hull University Teaching Hospitals, Hull York Medical School/ University of Hull, Hull, UK; Lucine VUITTON, CHU de Besançon - UMR, Université de Besançon, Franche-comté, France; Mehdi KAASSIS, Centre Hospitalier de Cholet, Cholet, France; Ally SPEIGHT, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, UK; Deb GHOSH, Princess Alexandra Hospital, Harlow, UK; Mark LÖWENBERG, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; Nicolas MATHIEU, CHU Grenoble,

Université Grenoble Alpes , Grenoble, France; Anne-Laure PELLETIER, Groupe Hospitalier Bichat-Claude Bernard, Paris, France; Anne PHILLIPS, York Hospital, Hull York Medical School, York, UK; Fernando MAGRO, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; Romain ALTWEGG, Hôpital Saint-Eloi, Montpellier, France; Irit AVNI BIRON, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Jonathon LANDY, Watford General Hospital, Watford, UK; Maria NACHURY, CHU Lille, Université Lille, Lille, France; Achuth SHENOY, Colchester General Hospital, Barts and The London School of Medicine and Dentistry Norwich Medical School Anglia Ruskin University, Colchester, UK; Caroline TRANG, CHU Nantes, Université Nantes , Nantes, France; Vered ABITBOL, Hôpital Cochin AP-HP, Université Paris Cité, Paris, France; Georgios BAMIAS, Sotiria General Hospital, National and Kapodistrian University, Athens, Greece; Klaudia FARKAS, Albert Szent-Györgyi Health center, University of Szeged, Szeged, Hungary; Christian MAASER, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; Ariella SHITRIT, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; Britta SIEGMUND, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; Jérôme FILIPPI, Hôpital L'archet, Nice, France; Colm O'MORAIN, Beacon Hospital, UCD, Dublin, Ireland; Henit YANAI, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Laurent COSTES, Centre hospitalier intercommunal de Créteil, Créteil, France; David HOBDAI, Sunderland Royal Hospital, Sunderland, UK; Zoltán SZEPEI, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Emma CALABRESE, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; Helen DALLAL, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, UK; Michael FUNG, NHS Plymouth, Plymouth, UK; Arvind RAMADAS, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, UK; Bijay BABURAJAN,

Maidstone Hospital, Maidstone, UK; Konrad KOSS, Macclesfield District General Hospital, Macclesfield, UK; Christophe BARBERIS, Hôpital Bagatelle, Talence, France; Anthony BUISSON, CHU Clermont-Ferrand, Inserm U1071, M2iSH, Université Clermont Auvergne, Clermont-Ferrand, France; Morgane AMIL, CHD Vendée, La Roche-sur-Yon, France; Paola BALESTRIERI, Campus Biomedico, Università Campus Biomedico, Roma, Italy; Matthew JOHNSON, Luton and Dunstable University Hospital, University College London, Luton, UK; Maria TZOUVALA, Agios Panteleimon General Hospital, Nikaia-Piraeus, Greece; Stéphanie VIENNOT, CHU Caen, Université de Caen, Caen, France; Andy LI, Worthing Hospital, Worthing, UK; Ferenc NAGY, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Nick THOMPSON, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, UK; Laurent ALRIC, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; Sunil SAMUEL, Nottingham University Hospitals NHS Trust Queen's Medical Centre, Nottingham, UK; Anne BOURRIER, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Elise CHANTELOUP, Hôpital Paris Saint-Joseph, Paris, France; Emilie DEL TEDESCO, CHU Saint-Etienne, Université Saint-Etienne, Saint-Etienne, France; Marcus HARBORD, Chelsea and Westminster Hospital, Imperial college london, London, UK; Alan LOBO, Royal Hallamshire Hospital, University of sheffield, Sheffield, UK; Sally MYERS, Hull University Teaching Hospitals, Hull York Medical School - University of Hull, Hull, UK; Richard POLLOK, St George's Hospital, University of London, London, UK; Tariq AHMAD, Royal Devon and Exeter Hospital, University of Exeter Medical School, Exeter, UK; Rakesh CHAUDHARY, Watford General Hospital, Watford, UK; Christos KARAKOIDAS, Naval Hospital, Athens, Greece; Edouard LOUIS, CHU de Liège, ULiège, Liège, Belgium; Ashraf SOLIMAN, Barnsley General Hospital, University of Sheffield, Barnsley, UK; Carmen STEFANESCU, Hôpital Beaujon, Université Paris, Clichy, France; Georgios THEOCHARIS, University Hospital of Patra, Patra, Greece; Stijn VANDEN BRANDEN, OLV-Aalst, Aalst,

Belgium; Belén BELTRAN , Hospital Universitari La Fe - Instituto de Investigación Sanitaria La Fe (IISLaFe), Polytechnic University of Valencia, Valencia, Spain; Yoram BOUHNİK, Hôpital Beaujon, Université de Paris, Clichy, France; Arnaud BOURREILLE, CHU Nantes, Université de Nantes , Nantes, France; Joana BRANCO, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; Ben COLLEYPRIEST, Royal United Hospitals Bath, Bath, UK; Rami ELIAKIM, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Paul KNIGHT, Wythenshawe Hospital, University of Manchester, Manchester, UK; Aoibhlinn O'TOOLE, Beaumont Hospital, RCSI, Dublin, Ireland; Virginia ROBLES, Hospital Vall d'Hebron, Universidad autonoma de Barcelona, universitat oberta de catalunya, Barcelona, Spain; Konstantinos TRIANTAFYLLOU, Attikon University Hospital, National and Kapodistrian University, Athens, Greece; Marta Maia BOSCA, Hospital Clinico Universitario de Valencia, University of Valencia, Valencia, Spain; Guy LAMBRECHT, AZ Damiaan, Ostend, Belgium; Lucia MARQUEZ MOSQUERA, Hospital del Mar. Barcelona, Pompeu Fabra University, Barcelona, Spain; Simon PANTER, South Tyneside District Hospital, South Shields, UK; Aikaterini PAPPA, University Hospital of Larissa, Larissa, Greece; Marion SIMON, Institut Mutualiste Montsouris, Paris, France; Ganesh SIVAJI, Harrogate District Hospital, Harrogate, UK; Christophe BELLANGER, Kremlin Bicêtre, Université Paris Saclay, Le Kremlin Bicêtre, France; Arthur BELLE, CHRU Nancy, Université de Nancy , Nancy, France; Natalia BORRUEL, Hospital Vall d'Hebron and Centro de Investigación Biomédica en Red de enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Barcelona, Barcelona, Spain; Laurence EGAN, UCHG, NUIG, Galway, Ireland; Harald PEETERS, AZ St-Lucas, Ghent, Ghent, Belgium; Daniel SHARPSTONE, West Suffolk Hospital, University of Suffolk, Suffolk, UK; Ramesh ARASARADNAM, University Hospital Coventry, University of Warwick, Coventry, UK; José Manuel BENITEZ, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación

Biomédica de Córdoba (IMIBIC), University of Cordoba, Córdoba, Spain; Jens Frederik DAHLERUP, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; Olga GIOULEME, Hippokration General Hospital, Aristotle University, Thessaloniki, Greece; Javier P. GISBERT, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Madrid (UAM), Madrid, Spain; Ulf HELWIG, Internistische Praxengemeinschaft Oldenburg, University of Kiel, Germany; Miguel MINGUEZ, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; Eftychia TSIRONI, Metaxa Memorial General Hospital, Pireaus, Greece; Angela VARIOLA, Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy; Patrick ALLEN, Ulster Hospital, Belfast, UK; Lucille BOIVINEAU, Hôpital Saint-Eloi, Montpellier, France; Andy COLE, Royal Derby Hospitals, Derby, UK; Nina DIB, CHU Angers, Université Angers, Angers, France; Fernando GOMOLLON, Hospital Clínico Universitario "Lozano Blesa", Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Zaragoza, Zaragoza, Spain; Richard JOHNSTON, Torbay Hospital, Torquay, UK; Konstantinos KATSANOS, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece; Nick KENNEDY, Royal Devon and Exeter Hospital University of Exeter Medical School, Exeter, UK; Marianne KISZKA-KANOWITZ, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; Ignacio MARIN-JIMENEZ, Hospital Universitario Gregorio Marañón, IiSGM, Complutense University of Madrid, Madrid, Spain; Pál MIHELLER, 1st Department of Surgery and Interventional Gastroenterology, Semmelweis University, Budapest, Hungary; Pilar NOS, Hospital Universitari La Fe, Instituto de Investigación Sanitaria La Fe (IISLaFe), Universitat Politècnica de Valencia, Valencia, Spain; Othman SARAJ, Scarborough Hospital, Hull York Medical School, Scarborough, UK; Lars

VINTER-JENSEN, Aalborg University Hospital, University of Aalborg, Aalborg, Denmark; Eran ZITTAN, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; Clotilde BAUDRY, Hôpital Saint-Louis, Université Paris Nord, Paris, France; Xavier CALVET, Hospital Universitari Parc Taulí, Autonomous University of Barcelona, Sabadell, Spain; Marie-Christine CAZELLES-BOUDIER, Centre Hospitalier de la Côte Basque, Bayonne, France; Jean-Louis COENEGRACHTS, Jessa Ziekenhuis Hospital, Hasselt, Belgium; Garret CULLEN, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Marco DAPERNO, Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; Anjan DHAR, Darlington Memorial Hospital, Durham, UK; Romain GERARD, CHU Lille, Université de Lille, Lille, France; Christian Lodberg HVAS, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; Nanna JENSEN, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; Nitsan MAHARSHAK, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Mark MCALINDON, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK; Simon MCLOUGHLIN, Christchurch Hospital, Christchurch, UK; Miles PARKES, Addenbrookes's Hospital, University of Cambridge, Cambridge, UK; Kamal PATEL, St George's Hospital, University of London, London, UK; Armando PEIXOTO, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; Dimitrios POLYMEROS, Attikon University Hospital, Athens, Greece; Francisco PORTELA, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal; Rodolfo ROCCA, Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; Philippe SEKSIK, Hôpital Saint Antoine, Sorbonne Université, Paris, France; Sreedhar SUBRAMANIAN, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Ruth TENNENBAUM, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France; Raja ATREYA, Universitätsklinikum

Erlangen, Universitätsklinikum Erlangen, Erlangen, Germany; Oliver BACHMANN, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; Arthur BERGER, CHU Angers, Université Angers, Angers, France; Renáta BOR, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Maire BUCKLEY, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Daniel CARPIO, Complejo Hospitalario Universitario de Pontevedra, University of Alcalá de Henares and the University of Granada, Pontevedra, Spain; María CHAPARRO, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Madrid (UAM), Madrid, Spain; Francesco COSTA, Azienda ospedaliero-universitaria pisana, Università di Pisa, Pisa, Italy; Eugeni DOMENECH, Hospital Universitari Germans Trias i Pujol Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat Autònoma Barcelona, Badalona, Spain; Maria ESTEVE, Hospital Universitari Mutua Terrassa. Centro Investigación biomédica en red de enfermedades hepáticas y digestivas, University of Barcelona, Barcelona, Spain; Stephen FOLEY, King's Mill Hospital, University of Nottingham, Sutton-in-Ashfield, UK; Jordi GUARDIOLA, Hospital Universitario de Bellvitge, IDIBELL, Universidad de Barcelona, Hospitalet del Llobregat, Spain; Ioannis KOUTROBAKIS, University Hospital of Heraklion, University of Crete, Heraklion, Greece; Tanja KUEHBACHER, Medius Kliniken Nürtingen, Medius Kliniken Nürtingen, Nürtingen, Germany; Cécilia LANDMAN, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Alessandro LAVAGNA, Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; Noemí MANCENÍDO, Hospital Universitario Infanta Sofía, European University of Madrid, San Sebastián de los Reyes, Spain; Míriam MAÑOSA, Hospital Universitari Germans Trias i Pujol Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Badalona, Spain;



Maria Dolores MARTÍN-ARRANZ, La Paz University Hospital, Universidad Autónoma de Madrid, Hospital La Paz Institute for Health Research, La Paz Hospital, Madrid, Spain; Laurianne PLASTARAS, CHU Colmar, Colmar, France; Maria Lia SCRIBANO, Ospedale S. Camillo-Forlanini, Roma, Italy; Subhasish SENGUPTA, Our Lady of Lourdes Hospital, RCSI, Drogheda, Ireland; Nils TEICH, Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten, Leipzig, Germany; My-Linh TRAN-MINH, Hôpital Saint-Louis, Université Paris Nord, Paris, France; Evanthia ZAMPELI, Alexandra General Hospital, Athens, Greece; Leila AMININEJAD, Erasmus Hospital, VUB-ULB, Brussels, Belgium; Teresa ARROYO, Hospital Clínico Universitario "Lozano Blesa", Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Zaragoza, Zaragoza, Spain; Alain ATTAR, Hôpital Beaujon, UFR de Médecine, Xavier Bichat, Université de Paris, Clichy la garenne, France; Ann-Sofie BACKMAN, Karolinska University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; Anita BÁLINT, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; John BECKLY, Royal Cornwall Hospital, University of Exeter Medical School, Truro, UK; Shomron BEN HORIN, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Sónia BERNARDO, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Ludovic CAILLO, Hôpital universitaire de Nîmes, Université Montpellier-Nîmes, Nîmes, France; Bénédicte CARON, Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France; María Shanika DE SILVA, Russells Hall Hospital, Dudley, UK; Anna FÁBIÁN, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Gionata FIORINO, IRCCS S. Raffaele, Università Vita-Salute San Raffaele, Milano, Italy; Ana GUTIERREZ, Hospital General Universitario Alicante, Centro de Investigación Biomédica en Red de enfermedades Hepáticas y Digestivas - ISABIAL, Instituto



de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain; Adi LAHAT, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Mohamed MASMOUDI, Hôpital de Meaux, Meaux, France; Marco MENDOLARO, Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; Vinciane MULS, CHU Saint-Pierre, VUB -ULB, Brussels, Belgium; Florian POULLENOT, CHU Bordeaux, Université de Bordeaux, Pessac, France; Christopher PROBERT, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Catherine REENAERS, CHU de Liège, ULiège, Liège, Belgium; Mariann RUTKA, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Zaman SARWARI, Odense University Hospital Svendborg, University of Odense, Svendborg, Denmark; Joanne SAYER, Doncaster Royal Infirmary, Doncaster, UK; Beatriz SICILIA, Hospital Universitario de Burgos, Burgos, Spain; Helena SOUSA, Centro Hospitalar Universitário do Algarve - Portimão, Portimão, Portugal; Catherine VAN KEMSEKE, CHU de Liège, ULiège, Liège, Belgium; Ana VIEIRA, Hospital Garcia Orta, Almada, Portugal; Yamile ZABANA, Hospital Universitari Mútua Terrassa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Terrassa, Spain; Marco ASTEGIANO, Ospedale San Giovanni antica sede, AOU Città della Salute e della Scienza di Torino, Torino, Italy; Paul BANIM, James Paget University Hospital, University of Suffolk, Great Yarmouth, UK; Dominik BETTENWORTH, Praxis für Innere Medizin, Münster, Germany; Médina BOUALIT, Hôpital de Valenciennes, Université de Lille, Valenciennes, France; Jacob Broder BRODERSEN, Hospital of Southwest Jutland, University of Southern Denmark, Esbjerg, Denmark; Angeliki CHRISTIDOU, Evangelismos General Hospital, Athens, Greece; Rachel COONEY, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK; João CORTEZ PINTO, Instituto Português Oncologia - Lisboa Francisco Gentil, Lisboa, Portugal; Marília CRAVO, Hospital Beatriz Ângelo, Loures,

Portugal; Anneline CREMER, Erasmus Hospital, VUB-ULB, Brussels, Belgium; Silvio DANESE, IRCCS S. Raffaele, Università Vita-Salute San Raffaele, Milano, Italy; Antonio DI SABATINO, Policlinico San Matteo, Università di Pavia, Pavia, Italy; Jan FALLINGBORG, Aalborg University Hospital, University of Aalborg, Aalborg, Denmark; Antonio FERRONATO, Ospedale Alto Vicentino AULSS 7 Pedemontana, Santorso, Italy; Esther GARCIA PLANELLA, Hospital de la Santa Creu i Sant Pau, Open University of Catalonia, Barcelona, Spain; Sanjay GUPTA, Croydon University Hospital, St George's, University of London King's College School of Medicine and Dentistry, Croydon, UK; Jonas HALFVARSON, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Eran ISRAELI, Wolfson Medical Center, Sackler Medical School Tel Aviv University, Tel Aviv, Israel; Samantha KESTENBAUM, Bristol Royal Infirmary, University of Bristol, Bristol, UK; Lone LARSEN, Aalborg University Hospital, University of Aalborg, Aalborg, Denmark; Elisabeth MACKEN, UZA, Antwerp University, Antwerp, Belgium; Nicoletta MATHOU, Konstantopoulou General Hospital, Athens, Greece; Ágnes MILASSIN, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Joanna POFELSKI, CH Annecy Genevois, Annecy, France; Chiara RICCI, Presidio Spedali Civili di Brescia, Università di Brescia, Brescia, Italy; Francisco RODRIGUEZ-MORANTA, Hospital Universitario de Bellvitge, IDIBELL, Hospitalet del Llobregat, Spain; Martin SCHMIDT-LAUBER, Praxis für Gastroenterologie Oldenburg, Oldenburg, Germany; Ian SHAW, Gloucester Royal Infirmary, Gloucester, UK; Marta SOARES, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal; Heithem SOLIMAN, Hôpital Louis Mourier, Université de Paris, Paris, France; Christos TRIANTOS, University Hospital of Patra, University of Patras, Patra, Greece; Konstantinos ZOGRAFOS, Athens Medical P. Faliron, Athens, Greece; Anurag AGRAWAL, Doncaster Royal Infirmary, Doncaster, UK; Alessandro ARMUZZI, IBD Center Humanitas Research Hospital, Rozzano Department of Biomedical

Sciences Humanitas University, Peive Emanuele, Milan, Italy; Alexandre AUBOURG, CHU Trousseau Tours, Université de Tours, Tours, France; Manuel BARREIRO-DE ACOSTA, Hospital Clínico Universitario de Santiago de Compostela, University of Santiago de Compostela, Santiago, Spain; Jesús BARRIO, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León (SACYL), Valladolid, Spain; Daniel BERGEMALM, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden ; Fernando BERMEJO, Hospital Universitario de Fuenlabrada, University Rey Juan Carlos, Madrid, Spain; Giorgia BODINI, Ospedale San Martino, Università di Genova, Genova, Italy; Johan BOHR, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Peter BOSSUYT, Imelda Hospital, Bonheiden, Belgium; Dimitrios CHRISTODOULOU, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece; Christophe CLAESSENS, AZ Turnhout, Turnhout, Belgium; Paul COLLINS, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Ruth DE FRANCISCO, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; Santiago GARCIA, Hospital Universitario Miguel Servet, Zaragoza University, Zaragoza, Spain; Sotirios GEORGOPOULOS, Athens Medical P. Faliron, Athens, Greece; Felix GOUTORBE, Centre Hospitalier de la Côte Basque, Bayonne, France; Chrisostomos KALANTZIS, Army Share Fund Hospital, Athens, Greece; Anastasia KOURIKOU, Hippokration General Hospital, Athens, Greece; Vincent MACE, CHD Vendée, La Roche-sur-Yon, France; Georgia MALAMUT, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France; Paula MINISTRO, Centro Hospitalar Tondela-Viseu, Viseu, Portugal; Isabelle NION LARMURIER, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Elena RICART, Hospital Clínic Barcelona Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

(CIBEREHD) IDIBAPS, University of Barcelona (UB), Barcelona, Spain; Mélanie SERRERO, Hôpital Nord Marseille, Université d'Aix-Marseille, Marseille, France; Juliette SHERIDAN, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Petra WEIMERS, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark; Vibeke ANDERSEN, Hospital of Southern Jutland, University of Southern Denmark, Aabenraa, Denmark; Bruno ARROJA, Hospital de Braga, Braga, Portugal; Bernd BOKEMEYER, Gastroenterologische Gemeinschaftspraxis Minden, Minden, Germany; Luis BUJANDA, Hospital Universitario de Donostia. Biodonostia Health Research Institute. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of the Basque Country (UPV/EHU), San Sebastián, Spain; Thibault DEGAND, CHU Dijon, Dijon, France; Carl ERIKSSON, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Cécile GARCEAU, CHD Vendée, La Rochesur-Yon, France; Henning GLERUP, Regional Hospital Silkeborg, University of Aarhus, Silkeborg, Denmark; Idan GOREN, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Lucina JACKSON, Bon Secours Hospital, UCC, Cork, Ireland; Stéphane KOCH, CHU Besançon, Université Besançon, Franche-comté, France; Francisco MESONERO, Hospital Universitario Ramón y Cajal, University of Alcalá de Henares, Madrid, Spain; Ingrid ORDAS, Hospital Clinic of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain; Pauline RIVIERE, CHU Bordeaux, Université de Bordeaux, Pessac, France; Simone SAIBENI, Ospedale di Rho, Rho, Italy; João SOARES, Hospital de Braga, Braga, Portugal; Noémie TAVERNIER, Hôpital Tourcoing, Université de Lille, Tourcoing, France; Klaus THEEDE, Hvidovre hospital, University of Copenhagen, Hvidovre, Denmark; Bella UNGAR, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Elke

BÄSTLEIN, Magen Darm Zentrum Wiener Platz, Köln, Germany; Antonio GASBARRINI, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Italy; Andreas PROTOPAPAS, AHEPA University Hospital, Thessaloniki, Greece; Wolfgang REINDL, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; Fabrizio BOSSA, Fondazione Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy; Ailsa HART, St Marks Hospital, Imperial college london, London, UK; Franz-Josef HEIL, Fachärztliche Schwerpunktpraxis für Magen-Darm-Erkrankungen, Andernach, Germany; Anthony O'CONNOR, TUH, TCD, Dublin, Ireland; Bas OLDENBURG, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; Luca PASTORELLI, Policlinico San Donato, Università di Milano, San Donato Milanese, Italy; Stephen PATCHETT, Beaumont Hospital, RCSI, Dublin, Ireland; Subramaniam RAMAKRISHNAN, Warrington Hospital, Warrington, UK; John De CAESTECKER, Leicester Royal Infirmary, Leicester University, Leicester, UK; Ana ECHARRI, Hospital ArquiStudy Coordinatorto Marcide, Complejo Hospitalario Universitario de Ferrol, University of Navarra, Ferrol, Spain; David KEVANS, St. James's Hospital, TCD, Dublin, Ireland; Jürgen BÜNING, Schwerpunktpraxis Gastroenterologie, Lübeck, Germany; Rosa COELHO, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; Jeroen JANSEN, OLVG oost, Amsterdam, The Netherlands; Benjamin KOSLOWSKI, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; Christopher WELLS, University Hospital of North Tees, Stockton, UK; Daniel CEBALLOS, Hospital Universitario de Gran Canaria Dr. Negrín, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; Daan De Konig, Gelre ziekenhuizen, Gelre, The Netherlands; Ingrid KÖNIG, Praxis Hopsital, Bautzen, Germany; Hari PADMANABHAN, Newcross Hospital, Wolverhampton, UK; Timi PATANI, Warrington Hospital, Warrington, UK; Raheel QURESHI, Queen Elizabeth Hospital, Newcastle University Medical School, Gateshead, UK; Edyta ZAGOROWICZ, The Maria

Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Matthieu ALLEZ, Hôpital Saint-Louis, Université Paris Nord, Paris, France; Emmanouil ARCHAVLIS, Evangelismos General Hospital, Athens, Greece; Delphine BONNET, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; Luisa GUIDI, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy; Deirdre MCNAMARA, TUH, TCD, Dublin, Ireland; Piero VERNIA, Policlinico Umberto I, Università La Sapienza, Roma, Italy; Michael WEIDENHILLER, Facharztzentrum Regensburg, Regensburg, Germany; Lang ALON, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Trine BOYSEN, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; Charlotte DELATTRE, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Richard FARRELL, Connolly Hospital, RCSI, Dublin, Ireland; Rolf-Achim KRÜGER, Praxengemeinschaft, Radebeul, Germany; Thierry PAUPARD, CH Dunkerque, Dunkerque, France; Bénédicte PROST, CH Saint-Joseph Saint-Luc, Lyon, France; Ida VIND, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; Flavio CAPRIOLI, Ospedale Maggiore Policlinico di Milano, Università di Milano, Milano, Italy; Vladimir GANCHO, Nykøbing Falster Sygehus, University of Copenhagen, Nykøbing Falster, Denmark; Vincent QUENTIN, Hôpital Yves Le Foll, Saint-Brieuc, France; Benjamin AVIDAN, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Geert D'HAENS, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; Jane MCCARTHY, Mercy University Hospital, UCC, Cork, Ireland; Jonathon SNOOK, Poole Hospital, Poole, UK; Konstantinos SOUFLERIS, Theageneio Cancer Hospital, Thessaloniki, Greece; Frank ZERBIB, CHU Bordeaux, Université de Bordeaux, Pessac, France; Dan CARTER, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Annekatrien DEPLA, Slotervaart ziekenhuis, Amsterdam, The Netherlands; Thomas EISENBACH, Praxengemeinschaft, Leverkusen, Germany; Walter FRIES, Policlinico G. Martino, Università

di Messina, Messina, Italy; Nikolaos GRAMMATIKOS, Hippokration General Hospital, Thessaloniki, Greece; Saskia ILEGEMS, Emmaüs ziekenhuis, AZ St-Maarten, Mechelen, Belgium; Antonio LOPEZ-SANROMAN, Hospital Universitario Ramón y Cajal, University of Alcalá de Henares, Madrid, Spain; Jacques MOREAU, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; Gabriele RIEGLER, Azienda ospedaliera Seconda Università di Napoli, Seconda Università di Napoli, Napoli, Italy; Svend RIETDIJK, OLVG oost, Amsterdam, The Netherlands; Marta ROCHA, Centro Hospitalar do Porto, Porto, Portugal; Isabelle ROSA, Centre hospitalier intercommunal de Créteil, Créteil, France; Barbara RYAN, TUH, TCD, Dublin, Ireland; Yelena YEREMENKO, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; Arnaud BORUCHOWICZ, Hôpital de Valenciennes, Université de Lille, Valenciennes, France; Filipe DAMIÃO, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Foteini LAOUDI, Athens Medical P. Faliro, Athens, Greece; Andreas LÜGERING, MVZ Portal 10, Münster, Germany; Giampiero MACARRI, Ospedale civile Augusto Murri, Fermo, Italy; Konstantinos THOMOPOULOS, University Hospital of Patra, University of Patras, Patra, Greece; Luísa BARROS, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal; Thomas BLIXT, Zealand University Hospital, University of Copenhagen, Koege, Denmark; Aurélien GARROS, CH Saint-Joseph Saint-Luc, Lyon, France; Sam KHORRAMI, Hospital Universitario Son Espases, Palma de Mallorca, Spain; Harry SOKOL, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Andreas STURM, DRK-Kliniken Berlin, DRK-Kliniken Berlin, Berlin, Germany; Dan LIVOVSKY, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; Jochen MAUL, MVZ für Gastroenterologie am Bayrischen Platz, Berlin, Germany; Heinrich MIKS, MVZ Hamm, Hamm, Germany; Vasileios PAPADOPOULOS, Attikon University Hospital, Athens, Greece; Carsten SCHMIDT, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; Yifat SNIR, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Lise



SVENNINGSSEN, Regional Hospital Herning, University of Aarhus , Herning, Denmark; Wafaa AHMED, Maidstone Hospital, Maidstone, UK; Yelena BROITMAN, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Emmanuel CUIILLERIER, Hôpital Victor Jousselin, Dreux, France; Prashant KANT, York Hospital, Hull York Medical School, York, UK; Jan LEYDEN, MMUH, UCD, Dublin, Ireland; Lev LICHTENSTEIN, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Susana LOPES, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; Chloé MARTINEAU, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Hugh MULCAHY , St Vincent University Hospital & University College Dublin, Dublin, Ireland; Axel SCHWEITZER, Gastroenterologische Gemeinschaftspraxis Münster, Münster, Germany; Fiona VAN SCHAİK, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; Hagar BANAI, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Pauline DANION, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; Charlotte DULERY, CHU Bordeaux, Université de Bordeaux, Pessac, France; Herma FIDDER, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; Claire GAY, Hôpital Lyon-Sud ,Université Lyon 1, Lyon, France; Hervé HAGEGE, Centre hospitalier intercommunal de Créteil, Créteil, France; Florence HARNOIS, CH Marne la vallée, Jossigny, France; Søren Peter JØRGENSEN, Aarhus University Hospital, University of Aarhus, Aarhus , Denmark; Jens MÜLLER-ZIEHM, Gastroenterologische Schwerpunktpraxis Hannover, Hannover, Germany; Michail OIKONOMOU, Euroclinic, Athens, Greece; Carolina PALMELA, Hospital Beatriz Ângelo, Loures, Portugal; Jörg SCHULZE/RÖSKE, Berufsausübungsgemeinschaft, Jerichow, Germany; Mark SMITH, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Tamar THURM, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Francesca BRESSO, Karolinska



University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; Hedia BRIXI, CHU de Reims, Université de Reims Champagne Ardenne, Reims, France; John JONES, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Pdraig MACMATHUNA, MMUH, UCD, Dublin, Ireland; Spyridon MICHPOULOS, Alexandra General Hospital, Athens, Greece; Claire PAINCHART, Hôpital de Valenciennes, Université de Lille, Valenciennes, France; Yulia RON, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Marianne VESTER-ANDERSEN, Zealand University Hospital, University of Copenhagen, Koege, Denmark; Gonçalo ALEXANDRINO, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; Norbert BÖRNER, Gastroenterologische Gemeinschaftspraxis Mainz, Mainz, Germany; Mariana CARDOSO, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; Cristina CHAGAS, Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; Axel DIGNAß, Agaplesion Krankenhaus Frankfurt, Agaplesion Krankenhaus Frankfurt, Frankfurt, Germany; Iris DOTAN, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Charlotte HEDIN, Karolinska University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; Pantelis KARATZAS, Laiko General Hospital, Athens, Greece; Panagiotis KASAPIDIS, Central Clinic, Athens, Greece; Károly PALATKA, 2nd Department of Internal Medicine, University of Debrecen, Debrecen, Hungary; Georgios SAKIZLIS, Latriko Athinon Hospital, Athens, Greece; Ana WILSON, St Marks Hospital, Imperial college london, London, UK; Nick BOSANKO, NHS Plymouth, Plymouth, UK; Paulo CALDEIRA, Centro Hospitalar Universitário do Algarve - Faro, Faro, Portugal; Charlotte GAGNIERE, Hôpital Henri Mondor, Université de Paris, Paris, France; Louise LIBIER, Hôpital Tourcoing, Université de Lille, Tourcoing, France; Camille MEUNIER, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; Gero MOOG, Gastroenterologische Facharztpraxis, Kassel, Germany; Audrey PASQUION, CH Saint-Joseph Saint-Luc, Lyon, France; Roberta PICA, Ospedale

Sandro Pertini, Roma, Italy; Ayesha AKBAR, St Marks Hospital, Imperial college london, London, UK; Nadia ARAB, Hôpital L'archet, Nice, France; Guillaume CADIOT, CHU de Reims, Université de Reims Champagne Ardenne, Reims, France; João CARVALHO, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal; Claire CHARPIGNON, Institut Mutualiste Montsouris, Paris, France; Klaus FELLERMANN, Praxisklinik Nürnberg, Praxisklinik Nürnberg, Freudenstadt, Germany; Sigal FISHMAN, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Gerald FRASER, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Nathan GLUCK, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Mark HOESL, Praxisklinik Nürnberg, Nürnberg, Germany; Jarosław KIERKUS, Children's Memorial Health Institute, Warsaw, Poland; Maria KLOPOCKA, Nicolaus Copernicus University in Toruń, Collegium Medicum, Bydgoszcz, Poland; Eduardo MARTIN ARRANZ, Hospital Universitario La Paz, Instituto de Investigacion Sanitaria La Paz (IDIPAZ), Madrid, Spain; Luis MENCHEN, Hospital Universitario Gregorio Marañón, IiSGM, Complutense University of Madrid, Madrid, Spain; Susanna NIKOLAUS, Universitätsklinikum Schleswig-Holstein, UKSH Kiel, Kiel, Germany; Anca PETRACHE, Vejle Hospital, University of Odense, Vejle, Denmark; Cyriel PONSIOEN, Amsterdam UMC Location AMC, Amsterdam, The Netherlands; Sabino RIESTRA, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; Pilar ROBLEDO, Hospital Universitario de Cáceres, University of Extremadura, Cáceres, Spain; Cristina RODRIGUEZ, Complejo Hospitalario de Navarra, Public University of Navarra, Pamplona, Spain; Misheal SAMER, Haameq Medical Center, Faculty of Medicine Technicion, Afula, Israel; Matthias TISCHER, Gastroenterologische Praxis Dresden, Dresden, Germany; Joanna WYPYCH, Copernicus Hospital, Gdańsk, Poland; Julien BAUDON, Centre Hospitalier de Cholet, Cholet, France;

Cristina BEZZIO, Ospedale di Rho, Rho, Italy; Gilles BOSCHETTI, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; Johan BURISCH, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; Tom CREED, Bristol Royal Infirmary, University of Bristol, Bristol, UK; Maria Giulia DEMARZO, Azienda ospedaliera universitaria San Martino, Università di Genova, Genova, Italy; Stefano FESTA, Ospedale San Filippo Neri, Roma, Italy; Andrés FIGUEROA, Hospital Universitario de Gran Canaria Dr. Negrín, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; Mette JULSGAARD, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; Pablo NAVARRO, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; Pablo PEREZ-GALINDO, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain; Cléa ROUILLON, CHU Caen, Université de Caen, Caen, France; Emanuele SABLICH, Ospedale di Rho, Rho, Italy; Joan TOSCA, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; Mathias VIDON, CHU Trousseau Tours, Créteil, France; Marine VIDON, CHRU Nancy, Université de Nancy, Nancy, France; René-Louis VITTE, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France; Anne WAMPACH, Centre hospitalier intercommunal de Créteil, Créteil, France;

#### **National Coordinators :**

Vered ABITBOL, Hôpital Cochin AP-AH, Université Paris Cité, Paris, France; Sebastian SHAJI, Hull University Teaching Hospitals - Hull York Medical School, University of Hull, Hull, UK; Livia BIANCONE, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; Alessandro ARMUZZI, IBD Center Humanitas Research Hospital, Rozzano Department of Biomedical Sciences Humanitas University, Peive Emanuele, Milan, Italy; Konstantinos KARMIRIS, Venizeleio General Hospital, Heraklion, Greece; Nikolaos VIAZIS, Evangelismos General Hospital, Athens, Greece; Eugeni DOMENECH, Hospital Universitari

Germans Trias i Pujol Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat Autònoma Barcelona, Badalona, Spain; Javier P. GISBERT, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad Autónoma de Madrid (UAM), Madrid, Spain; Peter BOSSUYT, Imelda General Hospital, Bonheiden, Belgium; Catherine REENAERS, CHU de Liège, ULiège, Liège, Belgium; Christian MAASER, Lüneburg Clinic, Lüneburg Clinic , Lüneburg, Germany; Britta SIEGMUND, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; Ulf HELWIG, Private Practice for Internal Medicine, University of Kiel, Germany; Johan BURISCH, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark; Mette JULSGAARD, Aarhus University Hospital, University of Aarhus , Aarhus, Denmark; Henit YANAI, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Uri KOPYLOV, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Glen DOHERTY, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Fernando MAGRO, Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal; Tamás MOLNAR, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Mark LöWENBERG, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; Bas OLDENBURG, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; Jonas HALFVARSON, Örebro University Hospital, Faculty of Medicine and Health of Örebro University, Örebro, Sweden; Ann-Sofie BACKMAN, Karolinska University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; Edyta ZAGOROWICZ, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Jarosław KIERKUS, Children's Memorial Health Institute, Warsaw, Poland;

**Methodologist / Biostatistician / Data manager :**

Cédric BAUMANN, UMDS CHRU Nancy - Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France; Isabelle CLERC URMES, UMDS CHRU Nancy - Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France; Hélène ROUSSEAU, UMDS CHRU Nancy - Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France; Marc BORIE, UMDS CHRU Nancy - Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France.

**Coders :**

Bénédicte CARON, Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France; Julien KIRCHGESNER, Hôpital Saint-Antoine, Sorbonne Université, Paris, France ; Mathieu UZZAN, Hôpital Henri Mondor, Université Paris Est, Créteil, France; Rachel COONEY, Queen Elizabeth Hospital, University Of Birmingham, Birmingham, UK; Kelly CHATTEN, Fairfield General Infirmary, Oldham, UK; Jimmy LIMDI, Northern Care Alliance NHS Foundation Trust, University of Manchester, Manchester, UK; Rimmer PETER, Queen Elizabeth Hospital, University Of Birmingham, Birmingham, UK; Iqbal TARIQ, Queen Elizabeth Hospital, University Of Birmingham, Birmingham, UK; Marta COSSIGNANI, Policlinico Tor Vergata, Università Di Roma Tor Vergata, Roma, Italy; Nikolaos VIAZIS, Evangelismos General Hospital, Athens Greece; Fiorella CAÑETE, Hospital Universitari Germans Trias I Pujol Centro De Investigación Biomédica En Red De Enfermedades Hepáticas Y Digestivas (CIBEREHD), Badalona, Spain ; Tom HOLVOET, Bird Group, Landegem, Belgium; Susanne KRASZ, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Petra WEIMERS, North Zealand Hospital, University Of Copenhagen, Hillerød, Denmark; Idan GOREN, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan\_Israel, Juliette SHERIDAN, St Vincent University

Hospital & University College Dublin, Dublin, Ireland; Sandra DIAS, Grupo De Estudo Da Doença Inflamatória Intestinal - GEDII, Porto, Portugal; Klaudia FARKAS, Albert Szent-Györgyi Health Center, University Of Szeged, Szeged, Hungary; Daniel BERGEMALM, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro\_Sweden; Edyta ZAGOROWICZ, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

### **Study Coordinators:**

Hadas ABALIA, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Aziza ABAZA, Hôpital de Meaux, Meaux, France; Gal ABRAMOVICH, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; Ingrid ACKZELL, Karolinska University Hospital, Stockholm, Sweden; Carol ADAMS, University Hospital of North Tees, Stockton, UK; Catherine ADDLETON, Royal Derby Hospitals, Derby, UK; Erika ALFAMBRA, Hospital Clínico Universitario "Lozano Blesa". Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Zaragoza, Spain; Alicia ALGABA, Hospital Universitario de Fuenlabrada, University Rey Juan Carlos, Madrid, Spain; Clare ALLCOCK, Russells Hall Hospital, Dudley, UK; Joanna ALLISON, Yeovil District Hospital, Yeovil, UK; Karine AMOURIAUX, CHU Nantes, Université de Nantes, Nantes, France; Julie ANDERSON, York Hospital, Hull York Medical School, York, UK; Emma ANDERSON, Our Lady of Lourdes Hospital, RCSI, Drogheda, Ireland; Saskia Appelmans, BIRD GROUP, Landegem, Belgium; Sophie ARMAND, CH Saint-Joseph Saint-Luc, Lyon, France; Lisa ARMSTRONG, Airedale General Hospital, Leeds University School of Medicine, Airedale,

UK; Stacey ATKINS, Torbay Hospital, Torquay, UK; Masoumeh ATTARAN-BANDARABADI, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; Yvonne BAILEY, TUH, TCD, Dublin, Ireland; Florian BÄR, Schwerpunktpraxis Gastroenterologie, Lübeck, Germany; Stephanie BARDOT, CHU Nantes, Université de Nantes, Nantes, France; Natasha BECK, Bristol Royal Infirmary, University of Bristol, Bristol, UK; Lillie BENNETT, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK; Jonathan Phil BERGFELD, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; Ramdane BERKANE, Hôpital de Meaux, Meaux, France; Marion BLIN, Hôpital Nord Marseille, Université Aix-Marseille, Marseille, France; Hanne BOEY, Imelda Hospital, Bonheiden, Belgium; Louise BOWLAS, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK; Joanne BRADLEY-POTTS, Wythenshawe Hospital, University of Manchester, Manchester, UK; Tracy BREAR, King's Mill Hospital, University of Nottingham, Sutton-in-Ashfield, UK; Nicole BRETLENDER-PETERS, MVZ Hamm, Hamm, Germany; Ellen BROWN, Darlington Memorial Hospital, Durham, UK; Johanna BROWN, Royal Derby Hospitals, Derby, UK; Elizabeth BUCKINGHAM, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Katrien BUELLENS, Emmaüs ziekenhuis, AZ St-Maarten, Mechelen, Belgium; Rhian BULL, Chelsea and Westminster Hospital, Imperial college london, London, UK; Maura Burke, UCHG, NUIG, Galway, Ireland; Leighanne BURNS, University Hospital Coventry, University of Warwick, Coventry, UK; Julie BURTON, Pinderfields Hospital, Wakefield, UK; Agness BWALYA, Harrogate District Hospital, Harrogate, UK; Karine CABANAS, CHU Nantes, Université de Nantes, Nantes, France; Muriel Callaghan, Connolly Hospital, RCSI, Dublin, Ireland; Océane CAMOU, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; Debbie CAMPBELL, Colchester General Hospital, Barts and The London School of Medicine and Dentistry Norwich Medical School Anglia Ruskin University,



Colchester, UK; Elvira CAPOFERRO, Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy; Mandy CARNAHAN, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Cornelia CARNIO, Universitätsklinikum Erlangen, Universitätsklinikum Erlangen, Erlangen, Germany; Anne CARTER, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Concetta CASALI CLACK, MVZ for Gastroenterology at Bayrischer Platz, Berlin, Germany; Leïla CHEDOUBA, Hôpital Saint-Louis, Université Paris Nord, Paris, France; Bessie CIPRIANO, St Bartholomew's Hospital, Queen Mary University of London, London, UK; Sophie CLAEYS, AZ St-Lucas, Ghent, Ghent, Belgium; Elizabeth CLAYTON, Pinderfields Hospital, Wakefield, UK; Manon CLOSSET, CHRU Nancy, Université de Nancy, Nancy, France; Dilek COBAN, CHU Clermont-Ferrand, Inserm U1071, M2iSH, Université Clermont Auvergne, Clermont-Ferrand, France; Sara COCOCCIA, Policlinico San Matteo, Pavia University, Pavia, Italy; Carolann COE, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Helen COLE, Royal Devon and Exeter Hospital, University of Exeter Medical School, Exeter, UK; Emilie COLLET, CHU Namur, Site Godinne, University of Namur, Namur, Belgium; Kayleigh COLLINS, Gloucester Royal Infirmary, Gloucester, UK; Isabelle COMBES, CH Annecy Genevois, Annecy, France; Emma CONNOR, Nottingham University Hospitals NHS Trust Queen's Medical Centre, Nottingham, UK; Kathryn CONSTANTIN, Watford General Hospital, Watford, UK; Susan COOKE, Chesterfield Royal Hospital, Chesterfield, UK; Nathanaëlle CORNET, CHU Angers, Angers, France; Estelle CORRIHONS, Centre Hospitalier de la Côte Basque, Bayonne, France; Pilar CORSINO, Hospital Universitario Miguel Servet, Zaragoza, Zaragoza University, Zaragoza, Spain; Rosie CORTAVILLE, Watford General Hospital, Watford, UK; Marta COSSIGNANI, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; Donna COTTERILL, Weston General Hospital, Weston-Super-Mare, UK; Amanda COWTON, Darlington Memorial



Hospital, Durham, UK; Harriet COX, York Hospital, Hull York Medical School, York, UK; Viktoria CRIPPS, Musgrove Park Hospital, Taunton, UK; Amanda CROWDER, Chesterfield Royal Hospital, Chesterfield, UK; Tzufit CUKIER, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; Amelia DANIEL, Princess Alexandra Hospital, Harlow, UK; Chris DAWE, Royal Bolton Hospital, Bolton, UK; Jose DE HAAN, Gelre ziekenhuizen, Gelre, The Netherlands; Rosanna DE LA CROIX, OLVG oost, Amsterdam, The Netherlands, Lien DECAESTEKER, AZ Delta, campus Rumbeke, Roeselare, Belgium; Evva DEJONCKHEERE, AZ Delta, campus Rumbeke, Roeselare, Belgium; Juan DELARE VILLANEGRO, Addenbrookes's Hospital, University of Cambridge, Cambridge, UK; Guillaume DELAVAL, CHU Caen, Université de Caen, Caen, France; Mariangela DELLIPONTI, Policlinico San Matteo, Pavia University, Pavia, Italy; Aude DELOMMEZ, CHU Lille, Université de Lille, Lille, France; Emilie DETRY, CHRU Nancy, Université de Nancy, Nancy, France; Melanie DHANARATNE, Ealing Hospital, Imperial college london, London, UK; Sandra DIAS, Grupo de Estudo da Doença Inflamatória Intestinal GEDII, Porto, Portugal; LAURA DIEZ GALAN, Hospital Universitario Miguel Servet, Zaragoza, Zaragoza University, Zaragoza, Spain; Marie DODEL, CHU Clermont-Ferrand, Inserm U1071, M2iSH, Université Clermont Auvergne, Clermont-Ferrand, France; Emma DOOKS, Airedale General Hospital, Leeds University School of Medicine, Airedale, UK; Joseph DU CHEYRON, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France ; Linda DUANE, UCHG, NUIG, Galway, Ireland; Helene Dukwen, Internistische Praxengemeinschaft Oldenburg, Kiel University, Oldenburg, Germany; Jennifer DULLING VULGO COCHRAN, MVZ for Gastroenterology at Bayrischer Platz, Berlin, Germany; Simona DYER, Scarborough Hospital, Hull York Medical School, Scarborough, UK; Harvey DYMOND, Weston General Hospital, Weston-Super-Mare, UK; Charlotte EKBLAD, Royal United Hospitals Bath, Bath, UK; Kerry ELLIOTT, Scarborough Hospital, Hull York Medical School, Scarborough, UK; Ingrid EMMERSON,

South Tyneside District Hospital, South Shields, UK; Irène EUGENE-JOLCHINE, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France ; Lorna FLEMING , Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Lorna FLEMING , Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Eve FLETCHER, Royal Cornwall Hospital, University of Exeter Medical School, Truro, UK; Sarah FORD, Hull University Teaching Hospitals, Hull York Medical School/ University of Hull, Hull, UK; Greg FORSHAW, York Hospital, Hull York Medical School, York, UK; Angela FOULDS, Torbay Hospital, Torquay, UK; Caroline FRANCOIS, Centre Hospitalier de CHOLET, Cholet, France; Nicole FUGE, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg , Germany; Gal GAFNI, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; Miri GANON, Wolfson Medical Center, Sackler Medical School Tel Aviv University, Tel Aviv, Israel; Olga GARCIA NUÑEZ, Hospital Universitario Gregorio Marañón, Madrid, Spain; Laura GARCIA RAMIREZ, Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP), Madrid, Spain; Sophie GELDER, Queen Elizabeth Hospital, Gateshead, UK; Raimonda GETTKOWSKI, Competence Network for Intestinal Diseases e.V., Kiel, Germany; Daniela GILARDI, Istituto clinico Humanitas, Rozzano, Italy; Paolo GIUFFRIDA, Policlinico San Matteo, Pavia University, Pavia, Italy; Vincent GOBERT, Hôpital de Meaux, Meaux, France; Jo GODDEN, West Suffolk Hospital , University of Suffolk, Suffolk, UK; Nuala GODWIN, Beaumont Hospital , RCSI, Dublin, Ireland; Kay GOULDEN, Fairfield General Infirmary, Oldham, UK; Sharon GRAHAM, Ulster Hospital, Belfast, UK; Charlotte GREEN, Barnsley General Hospital, University of Sheffield, Barnsley, UK; Marie GREEN, Newcross Hospital, Wolverhampton, UK; Aboubakar GUEYE, Groupe Hospitalier Bichat-Claude Bernard, Paris, France; Tuba GULER, Schwerpunktpraxis Gastroenterologie, Lübeck,

Germany; Ida GUSTAVSSON, Örebro University Hospital, Örebro, Sweden ; Helena HADJISAVVAS, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; Fiona HAMMONDS, Royal Cornwall Hospital, University of Exeter Medical School, Truro, UK; Christina HANTZI, Agaplesion Krankenhaus Frankfurt, Agaplesion Krankenhaus Frankfurt, Frankfurt, Germany; Marion HAUKE, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; Julie HAYDOCK , Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Julie HAYDOCK , Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Orla HAYES, St. James's Hospital , TCD, Dublin , Ireland; Lizette HELBO NISLEV, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark; Jessica HOCHSTODTER, Competence Network for Intestinal Diseases e.V., Kiel, Germany; Ashleigh HOGG, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, UK; Ashleigh HOGG, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, UK; Manuela HÖLBING, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; Maureen HOLLAND, Macclesfield District General Hospital, Macclesfield, UK; Maartje HOLSBERGEN , Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; Linda HOWARD, Yeovil District Hospital, Yeovil, UK; Aviya HOYDA, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; Robert HULL, Royal Bolton Hospital, Bolton, UK; Jane IRISH, St Bartholomew's Hospital, Queen Mary University of London, London, UK; Wendy JACKSON, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, UK; Wendy JANSSEN, AZ Turnhout, Turnhout, Belgium; Lesley JEFFREY , Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, UK; Lesley JEFFREY, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, UK; Sofia JOURDAN, CHU Dijon, Dijon, France; Izabela JUTROWSKA, Medical Network,

Warsaw, Poland; Chava KANIEL, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; Theofilos KAREZOS, EOMIFNE (Greek IBD Club), Athens, Greece; Niamh KELLY, Bon Secours, UCC, Cork, Ireland; Jessica KELLY, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Mary Kennedy, Connolly Hospital, RCSI, Dublin, Ireland; Una KENNEDY, St. James's Hospital, TCD, Dublin, Ireland; Joyce KIBARU, St George's Hospital, University of London, London, UK; Gemma KIRKMAN, Doncaster Royal Infirmary, Doncaster, UK; Janine KLAPROTH, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; Corinna KNEESE, Schwerpunktpraxis Gastroenterologie, Lübeck, Germany; Andrea KOCH, Competence Network for Intestinal Diseases e.V., Kiel, Germany; Kathleen KOKKE, AZ Turnhout, Turnhout, Belgium; Martha KOPPELOW, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; Susanne KRASZ, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Sabine KRAUSE, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; Sabine KRAUSPE, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; Petra KWAKKENBOS, Slotervaart ziekenhuis, Amsterdam, The Netherlands; Nunzia LABARILE, Policlinico di Bari, Università di Bari, Bari, Italy; Hannah LANG, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; Marianne LASSAILLY, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; Martine LECONTE, CHU Amiens, Université de Picardie Jules Verne, Amiens, France; Linda LEPCZYNSKI, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; Emma LEVELL, Hampshire Hospitals, University of Southampton, Basingstoke, UK; Nina LEVHAR, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Kerstin LINDHORT, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; Jessica LISLE, Hull University Teaching Hospitals, Hull York Medical School, University of Hull,

Hull, UK; Beatriz LOPEZ CAUCE, Hospital Universitario Gregorio Marañón, Madrid, Spain; Gabriele LORENZ, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; Ambra LOVATI, Ospedale Maggiore Policlinico di Milano, Università di Milano, Milano, Italy; Tracey LOWRY, Pinderfields Hospital, Wakefield, UK; Margareta LUND, Örebro University Hospital, Örebro, Sweden; Anne LUTZ VORDERBRÜGGE, Gastroenterologische Gemeinschaftspraxis Mainz, Mainz, Germany; Suzanne MAANSSON, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark; Videsheka MADAPATHAGE, Hôpital de Meaux, Meaux, France; Maelys CHEVIAKOFF, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; Alison MAGNESS, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Orla MANLEY, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Catherine MANYONI, Torbay Hospital, Torquay, UK; Ingke MARG, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; Antonella MARRA, Policlinico di Bari, Università di Bari, Bari, Italy; Carole MARTINS, Hôpital Beaujon, Université de Paris, Clichy, France; Arianna MASSELLA, Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy; Aurore MATHIAS, CHU Bordeaux, Pessac, France; Karin MENZEL, MVZ Portal 10, Münster, Germany; Danielle MERVYN, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Charlotte MINSART, Erasmus Hospital, VUB-ULB, Brussels, Belgium; Sally MITCHELL, Airedale General Hospital, Leeds University School of Medicine, Airedale, UK; Kathleen MONKS, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, UK; Mélanie MONTERO, CHRU Nancy, Université de Nancy, Nancy, France; Alson MOORE, Leicester Royal Infirmary, Leicester University, Leicester, UK; Maren MOSER, Competence Network for Intestinal Diseases e.V., Kiel, Germany; Alison MOSS, Musgrove Park Hospital, Taunton, UK; Angela MULLEN, MMUH, UCD, Dublin,

Ireland; M<sup>a</sup> Francisca MURCIANO, Hospital del Mar. Barcelona, Autonomous University of Barcelona, Barcelona, Spain; Deanna NAYLOR, Colchester General Hospital, Barts and The London School of Medicine and Dentistry Norwich Medical School Anglia Ruskin University, Colchester, UK; Ansgar NEHUS, Praxis für Innere Medizin, Münster, Germany; Anne NICHOLSON, Basildon and Thurrock University Hospitals NHS Trust, Basildon, UK; Sarah NÖDING, Agaplesion Krankenhaus Frankfurt, Agaplesion Krankenhaus Frankfurt, Frankfurt, Germany; Sinead Nolan , Bon Secours, UCC, Cork, Cork; Janet NÖRENBERG, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; Clare NORTHCOTT, NHS Plymouth, Plymouth, UK; Pauline OATES, Sunderland Royal Hospital, Sunderland, UK; Jim O'Connell, St. James's Hospital , Dublin , Ireland; Alison o'kelly, Colchester General Hospital, Barts and The London School of Medicine and Dentistry Norwich Medical School Anglia Ruskin University, Colchester, UK; Noam ORBACH-ZINGBOIM, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Judit OROBITG, Hospital Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain; Charlene OTIENO, Royal Derby Hospitals, Derby, UK; Charlotte OWEN, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Sarah Patch, Poole Hospital, Poole, UK; Maor PAUKER, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Renate PAULI, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; Harriet PEARSON, York Hospital, Hull York Medical School, York, UK; FALGON PEGGY, Hôpital Lyon-Sud, Université Lyon 1 , Lyon, France; Séverine PETIT, CHRU Nancy, Université de Nancy, Nancy, France; Christine PETRISSANS, Centre Hospitalier de la Côte Basque, Bayonne, France; Simona PIERGALLINI, Ospedale civile Augusto Murri, Fermo, Italy; Lucy PIPPARD, Yeovil District Hospital, Yeovil, UK; Laura PITT, York Hospital, Hull York Medical School, York, UK; Gabriella PÓCSIK, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Yoann POHER, Nord

Marseille, Université d'Aix-Marseille, Marseille, France; Chloé POMES, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; Lucy PRITCHARD, NHS Plymouth, Plymouth, UK; Laura PUCHADES, Hospital Clinico Universitario de Valencia, University of Valencia, Valencia, Spain; Sheena QUAID, Ealing Hospital, Imperial college london, London, UK; Aleem RANA, St George's Hospital, University of London, London, UK; Aleem RANA, St George's Hospital, University of London, London, UK; Dana RAYNARD, Worthing Hospital, Worthing, UK; Mykla REILLY, Stepping Hill Hospital, Stockport, UK; Sonja REINERT, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; Manuela REINKNECHT, Gastroenterologische Facharztpraxis, Kassel, Germany; Baerbel RENNER, Universitätsklinikum Schleswig-Holstein, UKSH Kiel, Kiel, Germany; Rob Reynolds, TUH, TCD, Dublin, Dublin; Giulia RIZZUTO, Ospedale V. Cervello, Palermo University, Palermo, Italy; Matthew ROBINSON, Calderdale Royal Hospital, Halifax, UK; Joke ROBRECHTS, Imelda Hospital, Bonheiden, Belgium; Eva M<sup>a</sup> RODRIGUEZ, Hospital Universitario de La Princesa, GETECCU (Grupo Español de Trabajo En enfermedad de Crohn y Colitis Ulcerosa) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Madrid (UAM), Madrid, Spain; Efrat ROSENBLUM, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; Tamlyn RUSSEL, Musgrove Park Hospital, Taunton, UK; Ibiyemi SADARE, NHS Plymouth, Plymouth, UK; Noa SALAMA, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Toos SCHAKEL, OLVG oost, Amsterdam, The Netherlands; Anja SCHAUER, Medizinsiche Klinik Fulda, Medizinsiche Klinik Fulda, Fulda, Germany; Elisa SCHIAVONI, Policlinico A. Gemelli, Fondazione Policlinico Universitario Gemelli, Roma, Italy; Caroline SHAW, Connolly Hospital, RCSI, Dublin, Ireland; Sarah SHELTON, King's Mill Hospital, University of Nottingham, Sutton-in-Ashfield, UK; Virginie SICART, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; Elodie SIOUVILLE, CHU Nantes,



Université de Nantes, Nantes, France; Orla SMITH, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Théo SOUDE, CHU Nantes, Université de Nantes, Nantes, France; Sophie STEPHENSON, Bradford Teaching Hospitals, Leeds School of Medicine, Bradford, UK; Elaine STEPHENSON, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, UK; Marjan STEPPE, BIRD GROUP, Landegem, Belgium; An STERKX, OLV-Aalst, Aalst, Belgium; Jo STICKLEY, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Jo STICKLEY, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Jo STICKLEY, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Kathleen SUGRUE, Mercy University Hospital, UCC, Cork, Ireland; Natalia SWIETEC, UZ Ghent, Ghent University, Ghent, Belgium; Charlotte TASIAUX, CHU Namur, site Godinne, University of Namur, Namur, Belgium; Bhavneet THAMU, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK; Susane THOMAS, Universitätsklinikum Carl Gustav Carus, University Hospital Carl Gustav Carus, Dresden, Germany; Ogwa TOBI, Watford General Hospital, Watford, UK; Kahina TOUABI, CHRU Nancy, Université de Nancy, Nancy, France; Shifra TOVI, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Julie TREGONNING, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, UK; Laura TURCHINI, Policlinico A. Gemelli, Fondazione Policlinico Universitario Gemelli, Roma, Italy; Julia UNKHOFF, Gastroenterologische Gemeinschaftspraxis Münster, Münster, Germany; Olesya UNRUH, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; Nurcan UZUN, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; Frauke VAN AERT, UZA, Antwerp University, Antwerp, Belgium; Sandrine VANDEN BERGH, Chwapi, Tournai, Belgium; Louise VANDENBROUCKE, AZ Damiaan, Ostend, Belgium; Laura



VANSTEENKISTE, BIRD GROUP, Landegem, Belgium; Shay VARDIT, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Valentin VERGRIETE, CH Dunkerque, Dunkerque, France; Elaine WALKER, Watford General Hospital, Watford, UK; Eleanor WARNER, Maidstone Hospital, , Maidstone, UK; Olivia WATCHORN, Leicester Royal Infirmary , Leicester University, Leicester, UK; Ekaterina WATSON, Ealing Hospital, Imperial college london, London, UK; Marie-Claire WAUTHIER, CHU St-Pierre, VUB -ULB, Brussels, Belgium; Maria WEETMAN, University Hospital of North Tees, Stockton, UK; Margaret WESTON, Leicester Royal Infirmary, Leicester University, Leicester, UK; Wiebke WEST-PETROSCHKA, Universitätsklinikum Schleswig-Holstein, UKSH Kiel, Kiel, Germany; Susann WIENECKE, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; Kerstin WIERLING, Gastroenterologische Gemeinschaftspraxis Münster, Münster, Germany; Miriam WIESTLER, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; Rebecca WILCOX, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Elva WILHELMSEN, James Paget University Hospital, University of Suffolk, Great Yarmouth, UK; Angharad WILLIAMS, West Suffolk Hospital , University of Suffolk, Suffolk, UK; Georgina WILLIAMSON, Wythenshawe Hospital, University of Manchester, Manchester, UK; Deborah WILSON, University Hospital of North Tees, Stockton, UK; Kate WISTANCE, Royal Shrewsbury Hospital, Keele University School of medicine, Staffordshire University, Shrewsbury, UK; Nicolas WORTMANN, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; Subie WURIE, University Hospital Coventry, University of Warwick, Coventry, UK; Karin YADGAR, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; Gail YOUNG, Ulster Hospital, Belfast, UK; Megan YOUNG, Macclesfield District General Hospital, Macclesfield, UK.

**GETAID contributors :**

Julien AUCOUTURIER; Marie- Jo BERTIN; Hasnae BOUGRINE; Marie COISNON;  
Antoine DEFRANCE; Kati GUTIERREZ; Amel HAROUZ; Laure JERBER; Aida KHLIFI;  
Amina KIRATI; Nasaladjine LIWORO ; Maude LOGOLTAT; Charlotte MAILHAT;  
Chancely M'BAYI; Yasmina MEDANE; Dalal MERKHOUFA ; Saouda MOHAMED  
ELHAD; Bertille MONTHE; Fanny MOYON; Pascaline RABIEGA; Jennifer SEKELA;  
Charlotte THILLOY.

**SANOIA contributors (Digital interaction with patient):**

Naima HAMAMOUCHE, Frederic PARTISOTTI

**CleanWeb contributors (eCRF):**

Patrick BLANDIN; Hocine MOKHTARI; Laure COUTARD

## Supplementary table legends

**Table 1.** Family History of inflammatory bowel disease or cancer

**Table 2.** Previous surgeries


**Table 3.** Previous 5-ASA and corticosteroids treatments

**Table 4.** Previous Immunomodulators treatments

**Table 5.** Previous Biological treatments

**Table 6.** History of cancer

**Table 7.** History of vaccination and infection



\* Reconciliation at the end of the study

Figure 1a: ICARE Dataflow

## I-CARE EXECUTIVE COMMITTEE

Filip BAERT (BE)  
Laurent BEAUGERIE (FR)  
Laurent PEYRIN-BIROULET (FR)  
Jean-François RAHIER (BE)



## I-CARE OPERATIONAL TEAM GETAID (PARIS)

Charlotte MAILHAT (Project Director)  
Marie COISNON (Project Manager)  
Kati GUTIEREZ (Pharmacovigilance Director)  
Hasnae BOUGRINE (Datamanager)  
Antoine DEFRANCE (CRA)  
Jennifer SEKELA (Study coordinator)  
Bertille MONTHE (Pharmacovigilant)



## I-CARE METHODOLOGICAL TEAM PARC (NANCY)

Cédric BAUMANN (Methodologist)  
Hélène ROUSSEAU (Statistician)



## I-CARE CC

Julien KIRCHGESNER (coder referent)  
Daniel BERGEMALM (SE)  
Fiorella CANETE PIZARRO (ES)  
Benedicte CARON (FR)  
Kelly CHATTEN (UK)  
Rachel COONEY (UK)  
Marta COSSIGNANI (IT)  
Sandra DIAS (PT)  
Kludia FARKAS (HU)  
Idan GOREN (IL)  
Tom HOLVOET (BE / NL)  
Tariq IQBAL (UK)  
Susanne KRASZ (DE)  
Jimmy LIMDI (UK)  
Peter RIMMER (UK)  
Juliette SHERIDAN (IE)  
Mathieu UZZAN (FR)  
Nikos VIAZIS (GR)  
Petra WEIMERS (DK)  
Edyta ZAGOROWICZ (PL)

## PATIENT PLATFORM E-HEALTH SERVICES SANOIA (GEMENOS)

Naïma HAMAMOUCHE- SERVY  
Frederic PARTISOTTI



## Journal Pre-proof

## COORDINATOR

### GROUP

Vered ABITBOL (FR)  
Alessandro ARMUZZI (IT)  
Ann-Sofie BECKMAN (SE)  
Livia BIANCONE (IT)  
Peter BOSSUYT (BE)  
Johan BURISCH (DK)  
Glen DOHERTY (IE)  
Eugeni DOMÈNECH (ES)  
Javier GISBERT (ES)  
Jonas HALFVARSON (SE)  
Ulf HELWIG (DE)  
Mette JULSGAARD (DK)  
Konstantinos KARMIRIS (GR)  
Jaroslaw KIERKUS (PL)  
Uri KOPYLOV (IL)  
Mark LOWENBERG (NL)  
Christian MAASER (DE)  
Fernando MAGRO (PT)  
Tamás MOLNAR (HU)  
Bas OLDENBURG (NL)  
Catherine REENAERS (BE)  
Sebastian SHAJI (UK)  
Britta SIEGMUND (DE)  
Nikolaos VIAZIS (GR)  
Henit YANAI (IL)  
Edyta ZAGOROWICZ (PL)

### eCRF

## TENTELEMEDECINE TECHNOLOGIES- CLEANWEB (PARIS)

Patrick BLANDIN  
Hocine MOKHTARI  
Laure COUTARD



## I-CARE SCIENTIFIC COMMITTEE

### EXECUTIVE COMMITTEE MEMBERS

Filip BAERT (BE)  
Laurent BEAUGERIE (FR)  
Laurent PEYRIN-BIROULET (FR)  
Jean-François RAHIER (BE)

### NATIONAL COORDINATOR GROUP

Vered ABITBOL (FR)  
Alessandro ARMUZZI (IT)  
Ann-Sofie BECKMAN (SE)  
Livia BIANCONE (IT)  
Peter BOSSUYT (BE)  
Johan BURISCH (DK)  
Glen DOHERTY (IE)  
EUGENI DOMÈNECH (ES)  
JAVIER GISBERT (ES)  
Jonas HALFVARSON (SE)  
Ulf HELWIG (DE)  
Mette JULSGAARD (DK)  
Konstantinos KARMIRIS (GR)  
Jaroslaw KIERKUS (PL)  
Uri KOPYLOV (IL)  
Mark LOWENBERG (NL)  
Christian MAASER (DE)  
Fernando MAGRO (PT)  
Tamás MOLNAR (HU)  
Stephane NAHON (FR)  
Bas OLDENBURG (NL)  
Catherine REENAERS (BE)  
Sebastian SHAJI (UK)  
Britta SIEGMUND (DE)  
Nikolaos VIAZIS (GR)  
Henit YANAI (IL)  
Edyta ZAGOROWICZ (PL)

### GETAID

Charlotte MAILHAT (Project Director)  
Marie COISNON (Project Manager)



Figure 1b: I-Care contributors




Figure 1c: Some history of I-Care



# I-CARE STUDY GROUP

Vered ABITBOL	Paola BALESTRIERI	Renáta BOR	João CARVALHO	Daan DE KONING	Jerome FILIPPI	Luisa GUIDI	Nick KENNEDY
Georges ABOUDA	Anita BALINT	Norbert BÖRNER	Fabiana CASTIGLIONE	Shanika DE SILVA	Gionata FIORINO	Sanjay GUPTA	Samantha KESTENBAUM
Anurag AGRAWAL	Giorgos BAMIAS	Natalia BORRUEL	Christine CAZELLES BOUDIER	Martine DE VOS	Sigal FISHMAN	Ana GUTIÉRREZ	David KEVANS
Tariq AHMAD	Hagar BANAI	Arnaud BORUCHOWICZ	Daniel CEBALLOS	Thibault DEGAND	Stephen FOLEY	Herve HAGEGE	Sam KHORRAMI
Wafaa AHMED	Paul BANIM	Nick BOSANKO	MIARD Céline	Emilie DEL TEDESCO	Ginette FOTSING	Jonas HALFVARSON	Julien KIRCHGESNER
Ayesha AKBAR	Christophe BARBERIS	Marta Maia BOSCÁ	Cristina CHAGAS	Charlotte DELATTRE	Denis FRANCHIMONT	Marcus HARBORD	Marianne KISZKA-KANOWITZ
Gonçalo ALEXANDRINO	Manuel BARREIRO	Fabrizio BOSSA	EliseCHANTELOUP	Anne Catherine DEPLA	Gerald FRASER	Florence HARNOIS	Maria KLOPOCKA
Patrick ALLEN	Jesús BARRIO	Peter BOSSUYT	María CHAPARRO	Marie DEWITTE	Walter FRIES	Ailsa HART	Paul KNIGHT
Matthieu ALLEZ	Luisa BARROS	Médina BOUALIT	Claire CHARPIGNON	Geert D'HAENS	Mathurin FUMERY	Peter HASSELBLATT	Stéphane KOCH
Lang ALON	Elke BÄSTLEIN	Guillaume BOUGUEN	Rakesh CHAUDHARY	Anjan DHAR	Michael FUNG	Xavier HEBUTERNE	Ingrid KÖNIG
Laurent ALRIC	Clotilde BAUDRY	Yoram BOUHNİK	Angeliki CHRISTIDOU	Antonio DI SABATINO	Charlotte GAGNIERE	Charlotte HEDIN	Uri KOPYLOV
Romain ALTWEGG	Laurent BEAUGERIE	Arnaud BOURREILLE	Dimitrios CHRISTODOULOU	Nina DIB	Emmanuel GALOO	Franz Josef HEIL	Benjamin KOSLOWSKI
Sylvain AMBREGNA	John BECKLEY	Anne BOURRIER	Christophe CLAESSENS	Axel DIGNAß	Vladimir GANCHO	Frederic HELUWAERT	Konrad KOSS
Morgane AMIL	Andrew BELL	Trine BOYSEN	Rosa COELHO	Renata D'INCA	Mohsin GANGI	Ulf HELWIG	Ioannis KOUTROUBAKIS
Leila AMININEJAD	Guy BELLÁICHE	Joana BRANCO	Jean-Louis COENEGRACHTS	Glen DOHERTY	Cécile GARCEAU	David HOBDAY	Rolf KRÜGER
Aurélien AMIOT	Christophe BELLANGER	Francesca BRESSO	Andy COLE	Eugeni DOMÈNECH	Santiago GARCÍA	Mark HOESL	Tanja KÜHBACHER
Vibeke ANDERSEN	Arthur BELLE	Hedia BRIXI	Ben COLLEYPRIEST	Iris DOTAN	Esther GARCIA-PLANELLA	Clémence HORAIST	David LAHARIE
Ramesh ARASARADNAM	Belén BELTRÁN	Jacob Broder BRODERSEN	Paul COLLINS	Patrick DUBOIS	Antonio GASBARRINI	Christian Lodberg HVAS	Adi LAHAT
Emmanuel ARCHAVLIS	Shomron BEN HORIN	Yelena BROITMAN	Rachel COONEY	Charlotte DULERY	Claire GAY	Saskia ILEGEMS	Guy Lambrecht
Peixoto ARMANDO	José Manuel BENÍTEZ	Maire BUCKLEY	Lynsey CORLESS	Ana ECHARRI	Sotirios GEORGOPOULOS	Eran ISRAELI	Cecilia LANDMAN
Franco ARMELAO	Daniel BERGEMALM	Anthony BUISSON	João CORTEZ PINTO	Piotr EDER	Romain GERARD	Lucina JACKSON	Jonathan LANDY
Alessandro ARMUZZI	Arthur BERGER	Luis BUJANDA	Francesco COSTA	Laurence EGAN	Deb GHOSH	Jeroen JANSEN	Fotini LAOUDI
Bruno ARROJA	Fernando BERMEJO	Jürgen BÜNING	Laurent COSTES	Thomas EISENBACH	Cyrielle GILLETTA	Kierkus JAROSLAW	Lone LARSEN
Maria Teresa ARROYO	Sonia BERNARDO	Jeffrey BUTTERWORTH	Marilia CRAVO	Khaldoun EL RIZ	Olga GIOULEME	Nanna Martin JENSEN	Alessandro LAVAGNA
Marco ASTEGIANO	Dominik BETTENWORTH	Guillaume CADIOT	Anneline CREMER	Rami ELIAKIM	Javier GISBERT	Matthew JOHNSON	Eric LE BALC
Raja ATREYA	Livia BIANCONE	Ludovic CAILLO	Emmanuel CUILLERIER	David ELPHICK	Henning GLERUP	Richard JOHNSTON	Jan LEYDEN
Alain ATTAR	Pierre BLANC	Emma CALABRESE	Garret CULLEN	Carl ERIKSSON	Nathan GLUCK	John JONES	Andy LI
Alexandre AUBOURG	Thomas BLIXT	Paulo CALDEIRA	Jens Frederik DAHLERUP	Maria ESTEVE	Fernando GOMOLLÓN	Søren Peter JØRGENSEN	Louise LIBIER
Benjamin AVIDAN	Giorgia BODINI	Xavier CALVET	Helen DALLAL	Anna FABIAN	John GORDON	Mehdi KAASSIS	Lev LICHTENSTEIN
Irit AVNI BIRON	Johan BOHR	Flavio CAPRIOLI	Filipe DAMIAO	Jan FALLINGBORG	Idan GOREN	Chrysostomos KALANTZIS	Jimmy LIMDI
Bijay BABURAJAN	Lucile BOIVINEAU	Mariana CARDOSO	Silvio DANESE	Klaudia FARKAS	Jean-Marc GORNET	Christos KARAKOIDAS	Dan LIVOVSKY
Oliver BACHMANN	Bernd BOKEMEYER	Bénédicte CARON	Marco DAPERNO	Richard FARRELL	Félix GOUTORBE	Konstantinos KARMIRIS	Alan LOBO
Ann-Sofie BACKMAN	Delphine BONNET	Daniel CARPIO	John DE CAESTECKER	Antonio FERRONATO	Nikolaos GRAMMATIKOS	Panagiotis KASAPIDIS	Christophe LOCHER
Filip BAERT	Joelle BONNET	Dan CARTER	Ruth DE FRANCISCO	Herma FIDDER	Jordi GUARDIOLA	Konstantinos KATSANOS	Susana LOPES



# I-CARE STUDY GROUP

Antonio LÓPEZ SANROMÁN	Luís MENCHÉN	Aoibhlinn O'TOOLE	Christopher PROBERT	Carsten SCHMIDT	Konstantinos SOUFLERIS	Piero VERNIA
Edouard LOUIS	Marco MENDOLARO	Hari PADMANABHAN	Benedicte PROST	Martin SCHMIDT-LAUBER	Helena SOUSA	Marianne VESTER-ANDERSEN
Mark LOWENBERG	Francisco MESONERO	Károly PALATKA	Andreas PROTOPAPAS	Manon SCHOULER	Ally SPEIGHT	Nikolaos VIAZIS
Andreas LÜGERING	Georgios MICHALOPOULOS	Carolina PALMELA	Vincent QUENTIN	Jörg SCHULZE	Michael SPRAKES	Ana VIEIRA
Christian MAASER	Christophe MICHIELS	Simon PANTER	Raheel QURESHI	Axel SCHWEITZER	Anca STAICU	Stéphanie VIENNOT
Padraig MAC MATHUNA	Spyridon MICHPOULOS	Georgios PAPTAEODORIDIS	Jean-François RAHIER	Maria Lia SCRIBANO	Carmen STEFANESCU	Ida VIND
Gilles MACAIGNE	Pál MIHELLER	Claudio PAPI	Subramaniam RAMAKRISHNAN	Shaji SEBASTIAN	Andreas STURM	Lars VINTER-JENSEN
Giampiero MACARRI	Heinrich MIKS	Benjamin PARIENTE	Catherine REENAERS	Philippe SEKSIK	Sreedhar SUBRAMANIAN	Lucine VUITTON
Vincent MACE	Ágnes MILASSIN	Gareth PARKES	Jean-Marie REIMUND	Subhasish SENGUPTA	Lise SVENNINGSEN	Michael WEIDENHILLER
Elisabeth MACKEN	Miguel MÍNGUEZ	Miles PARKES	Wolfgang REINDL	Mélanie SERRERO	Zoltán SZEPEZ	Petra WEIMERS
Fernando MAGRO	Paula MINISTRO	Luca PASTORELLI	Elena RICART	Sohail SHARIQ	Noémie TAVERNIER	Christopher WELLS
Nitsan MAHARSHAK	Tamás MOLNAR	Timi PATANI	Chiara RICCI	Daniel SHARPSTONE	Niels TEICH	Emma WESLEY
Georgia MALAMUT	Gero MOOG	Stephen PATCHETT	Gabriele RIEGLER	Ian SHAW	Ruth TENNENBAUM	Ana WILSON
Chrysoula MALLI	Jacques MOREAU	Kamal PATEL	Sabino RIESTRA	Richard SHENDEREY	Klaus THEEDE	Joanna WYPYCH
Noemí MANCENÍDO	Morgane MOURGUET	Thierry PAUPARD	Svend RIETDIJK	Achuth SHENOY	Georgios THEOCHARIS	Vasileios XOURGIAS
Spilios MANOLAKOPOULOS	Hugh MULCAHY	Natalia PEDERSEN	Pauline RIVIERE	Juliette SHERIDAN	Angeliki THEODOROPOULOU	Henit YANAI
Míriam MAÑOSA	Jens MÜLLER-ZIEHM	Harald PEETERS	Pilar ROBLEDO	Ariella SHITRIT	Konstantinos THOMOPOULOS	Yelena YEREMENKO
Gerassimos MANTZARIS	Vinciane MULS	Anne-Laure PELLETIER	Virginia ROBLES	Beatriz SICILIA	Nick THOMPSON	Yamile ZABANA
Ignacio MARÍN	Sally MYERS	Anca PETRACHE	Xavier ROBLIN	Britta SIEGMUND	Tamar THURM	Edyta ZAGOROWICZ
Costas MARKOGLOU	Maria NACHURY	Laurent PEYRIN-BIROULET	Rodolfo ROCCA	Nicolas SIGUR	Matthias TISCHER	Camille ZALLOT
Lucía MÁRQUEZ	Ferenc NAGY	Anne PHILLIPS	Marta ROCHA	Marion SIMON	Caroline TRANG POISSON	Eyanthia ZAMPELI
Eduardo MARTÍN ARRANZ	Stephane NAHON	Roberta PICA	Cristina RODRÍGUEZ	Salil SINGH	My-Linh TRAN-MINH	Sebastian ZEISSIG
Maria Dolores MARTÍN ARRANZ	Antoine NAKAD	Guillaume PINETON DE CHAMBRUN	Francisco RODRIGUEZ MORANTA	Elena SION	Konstantinos TRIANTAFYLLOU	Frank ZERBIB
Chloé Martineau	Stéphane NANCEY	Marie Pierre PINGANNAUD	Yulia RON	Ganesh SIVAJI	Christos TRIANTOS	Eran ZITTAN
Mohamed Ali MASMOUDI	Susanna NIKOLAUS	Laurianne PLASTARAS	Isabelle ROSA	Katie SMITH	Eftychia TSIRONI	Konstantinos ZOGRAFOS
Nicolas MATHIEU	Isabelle NION LARMURIER	Joanna POFELSKI	Mariann RUTKA	Mark SMITH	Maria TZOUVALA	
Nicoletta MATHOU	Pilar NOS	Vanessa POLIN	Barbara RYAN	Yifat SNIR	Bella UNGAR	
Jochen MAUL	Anthony O'CONNOR	Richard POLLOK	Simone SAIBENI	Jonathon SNOOK	Jean-Christophe VALATS	
Zia MAZHAR	Konstantinos OIKONOMOU	Dimitrios POLYMEROS	Georgios SAKIZLIS	Joao SOARES	Catherine VAN KEMSEKE	
Mark MCALINDON	Michail OIKONOMOU	Cyriel PONSIOEN	Misheal SAMER	Marta SOARES	Fiona VAN SCHAİK	
Jane McCARTHY	Bas OLDENBURG	Francisco PORTELA	Sunil SAMUEL	Harry SOKOL	Stijn VANDEN BRANDEN	
Simon MCLAUGHLIN	Colm O'MORAIN	Florian PoulLENOT	Othman SARAJ	Ashraf SOLIMAN	Deven VANI	
Deirdre McNAMARA	Ingrid ORDÁS	Cathryn PRESTON	Zaman SARWARI	Heithem SOLIMAN	Emmanouil VARDAS	
Maria MELA	Ambrogio ORLANDO	Maria Beatrice PRINCIPI	Joanna SAYER	Sunil SONWALKAR	Angela VARIOLA	



**Supplementary Table 1. Family History of inflammatory bowel disease or cancer**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Family history of IBD</b>										0.0263
No	8442	88.1		3382	89.0		5060	87.5		
Yes	1141	11.9		418	11.0		723	12.5		
Missing	623			237			386			
<b>Family history of lymphoma, colorectal cancer, melanoma, breast cancer</b>										0.0201
No	8485	88.7		3333	87.7		5152	89.1		
Yes	1085	11.3		466	12.3		619	10.7		
Missing	636			238			398			

\* Chi-square test

Abbreviation : IBD (Inflammatory Bowel Disease), SD (Standard Deviation)

**Supplementary Table 2. Previous surgeries**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Previous surgery</b>										<.0001
No	7473	73.2		3877	96.0		3596	58.3		
Yes	2733	26.8		160	4.0		2573	41.7		
<b>Proximal small bowel resection</b>										<.0001
No	10004	98.0		4036	100.0		5968	96.7		
Yes	202	2.0		1	0.0		201	3.3		
<b>Ileocaecal or ileal resection</b>										<.0001
No	8699	85.2		4034	99.9		4665	75.6		
Yes	1507	14.8		3	0.1		1504	24.4		
<b>Strictureplasty</b>										<.0001
No	10082	98.8		4036	100.0		6046	98.0		
Yes	124	1.2		1	0.0		123	2.0		
<b>Segmental colectomy</b>										<.0001
No	9855	96.6		4025	99.7		5830	94.5		
Yes	351	3.4		12	0.3		339	5.5		
<b>Subtotal colectomy with ileorectal anastomosis</b>										<.0001
No	10039	98.4		4015	99.5		6024	97.6		
Yes	167	1.6		22	0.5		145	2.4		
<b>Total proctocolectomy with ileoanal anastomosis</b>										0.7557
No	10119	99.1		4004	99.2		6115	99.1		
Yes	87	0.9		33	0.8		54	0.9		
<b>Surgical drainage of abdominal abscess</b>										<.0001
No	10038	98.4		4028	99.8		6010	97.4		
Yes	168	1.6		9	0.2		159	2.6		
<b>Permanent stoma</b>										<.0001
No	10085	98.8		4036	100.0		6049	98.1		
Yes	121	1.2		1	0.0		120	1.9		
<b>Perianal surgery</b>										<.0001
No	9345	91.6		3982	98.6		5363	86.9		
Yes	861	8.4		55	1.4		806	13.1		

\* Chi-square test

Abbreviation : SD (Standard Deviation)

**Supplementary Table 3. Previous 5-ASA and corticosteroids treatments**

	Total			Ulcerative colitis or IBD Unclassified			Crohn's Disease			p*
	N= 10206			N=4037 (39.6%)			N=6169 (60.4%)			
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Any oral form of 5-ASA</b>										
No	5967	63.6		2679	72.2		3288	58.0		<.0001
Yes	3413	36.4		1034	27.8		2379	42.0		
Missing	826			324			502			
<b>Foam, suppositories or enema form of 5-ASA</b>										
No	7223	76.4		2086	55.5		5137	90.2		<.0001
Yes	2229	23.6		1670	44.5		559	9.8		
Missing	754			281			473			
<b>Any form of systemic corticosteroids</b>										
No	3223	34.1		1344	35.7		1879	33.0		0.0063
Yes	6237	65.9		2420	64.3		3817	67.0		
Missing	746			273			473			
<b>Budesonide</b>										
No	7474	79.0		3496	92.8		3978	69.9		<.0001
Yes	1990	21.0		270	7.2		1720	30.1		
Missing	742			271			471			
<b>Budesonide MMX</b>										
No	9383	98.9		3701	98.2		5682	99.4		<.0001
Yes	106	1.1		69	1.8		37	0.6		
Missing	717			267			450			
<b>Beclometasone</b>										
No	9057	95.4		3425	90.9		5632	98.4		<.0001
Yes	434	4.6		344	9.1		90	1.6		
Missing	715			268			447			

\* Chi-square test

Abbreviations : 5-ASA (5-aminosalicylates), SD (Standard Deviation)

**Supplementary Table 4. Previous Immunomodulators treatments**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*	
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD		
<b>Azathioprine</b>											
No	7070	69.3		3161	78.3		3909	63.4		<.0001	
Yes	3136	30.7		876	21.7		2260	36.6			
<b>Azathioprine: Estimated duration of treatment before entry in I-CARE (years)</b>											
<1 year	1488	48.4		473	55.1		1015	45.8		.	
1 year	302	9.8		76	8.8		226	10.2			
2 years	309	10.1		79	9.2		230	10.4			
3 years	182	5.9		45	5.2		137	6.2			
4 years	163	5.3		45	5.2		118	5.3			
5 years	128	4.2		34	4.0		94	4.2			
6 years	119	3.9		28	3.3		91	4.1			
7 years	81	2.6		25	2.9		56	2.5			
8 years	57	1.9		12	1.4		45	2.0			
9 years	42	1.4		5	0.6		37	1.7			
10 years	47	1.5		8	0.9		39	1.8			
11 years	37	1.2		9	1.0		28	1.3			
12 years	36	1.2		4	0.5		32	1.4			
13 years	23	0.7		5	0.6		18	0.8			
14 years	11	0.4		4	0.5		7	0.3			
15 years	9	0.3		1	0.1		8	0.4			
16 years	13	0.4		1	0.1		12	0.5			
17 years	9	0.3		0	0.0		9	0.4			
18 years	4	0.1		1	0.1		3	0.1			
20 years	5	0.2		1	0.1		4	0.2			
21 years	2	0.1		0	0.0		2	0.1			
22 years	1	0.0		1	0.1		0	0.0			
24 years	1	0.0		0	0.0		1	0.0			
25 years	1	0.0		1	0.1		0	0.0			
26 years	1	0.0		0	0.0		1	0.0			
29 years	1	0.0		0	0.0		1	0.0			
>30 years	1	0.0		1	0.1		0	0.0			
Missing	63			17			46				
<b>6-Mercaptopurine</b>											
No	9728	95.3		3890	96.4		5838	94.6		<.0001	
Yes	478	4.7		147	3.6		331	5.4			
<b>6-Mercaptopurine: Estimated duration of treatment before entry in I-CARE (years)</b>											
<1 year	330	70.5		100	68.5		230	71.4		.	
1 year	44	9.4		15	10.3		29	9.0			
2 years	24	5.2		7	4.8		17	5.3			
3 years	20	4.3		4	2.7		16	5.0			
4 years	10	2.1		5	3.4		5	1.6			
5 years	6	1.3		3	2.1		3	0.9			
6 years	8	1.7		4	2.7		4	1.3			
7 years	6	1.3		3	2.1		3	0.9			
8 years	6	1.3		3	2.1		3	0.9			
9 years	4	0.9		1	0.7		3	0.9			
10 years	2	0.4		0	0.0		2	0.6			
11 years	2	0.4		1	0.7		1	0.3			
12 years	2	0.4		0	0.0		2	0.6			
14 years	1	0.2		0	0.0		1	0.3			
15 years	1	0.2		0	0.0		1	0.3			
16 years	1	0.2		0	0.0		1	0.3			
18 years	1	0.2		0	0.0		1	0.3			
Missing	10			1			9				
<b>Methotrexate</b>											
No	9568	93.7		3931	97.4		5637	91.4			<.0001
Yes	638	6.3		106	2.6		532	8.6			
<b>Methotrexate: Estimated duration of treatment before entry in I-CARE (years)</b>											

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<1 year	316	51.2		59	57.8		257	49.9		
1 year	99	16.0		15	14.7		84	16.3		
2 years	86	13.9		14	13.7		72	14.0		
3 years	33	5.3		6	5.9		27	5.2		
4 years	28	4.5		4	3.9		24	4.7		
5 years	14	2.3		0	0.0		14	2.7		
6 years	13	2.1		0	0.0		13	2.5		
7 years	10	1.6		2	2.0		8	1.6		
8 years	7	1.1		0	0.0		7	1.4		
9 years	3	0.5		0	0.0		3	0.6		
10 years	5	0.8		1	1.0		4	0.8		
12 years	1	0.2		1	1.0		0	0.0		
14 years	1	0.2		0	0.0		1	0.2		
15 years	1	0.2		0	0.0		1	0.2		
Missing	21			4			17			

\* Chi-square test

Abbreviation : SD (Standard Deviation)

**Supplementary Table 5. Previous Biological treatments**

	Total N= 10207			Ulcerative colitis or IBD Unclassified N=4038 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Infliximab</b>										<.0001
No	7790	82.2		3286	86.6		4504	79.2		
Yes	1690	17.8		507	13.4		1183	20.8		
Missing	726			244			482			
<b>Infliximab: Estimated duration of treatment before entry in I-CARE (years)</b>										.
<1 year	743	44.8		249	49.8		494	42.6		
1 year	269	16.2		92	18.4		177	15.3		
2 years	247	14.9		62	12.4		185	15.9		
3 years	145	8.7		36	7.2		109	9.4		
4 years	93	5.6		25	5.0		68	5.9		
5 years	55	3.3		12	2.4		43	3.7		
6 years	27	1.6		8	1.6		19	1.6		
7 years	30	1.8		7	1.4		23	2.0		
8 years	11	0.7		2	0.4		9	0.8		
9 years	16	1.0		3	0.6		13	1.1		
10 years	7	0.4		2	0.4		5	0.4		
11 years	4	0.2		1	0.2		3	0.3		
12 years	5	0.3		0	0.0		5	0.4		
13 years	1	0.1		1	0.2		0	0.0		
14 years	2	0.1		0	0.0		2	0.2		
15 years	4	0.2		0	0.0		4	0.3		
17 years	1	0.1		0	0.0		1	0.1		
Missing	30			7			23			
<b>Adalimumab</b>										<.0001
No	8186	86.0		3515	92.3		4671	81.8		
Yes	1334	14.0		292	7.7		1042	18.2		
Missing	686			240			456			
<b>Adalimumab: Estimated duration of treatment before entry in I-CARE (years)</b>										.
<1 year	562	42.9		184	64.1		378	36.9		
1 year	242	18.5		51	17.8		191	18.7		
2 years	185	14.1		27	9.1		158	15.4		
3 years	131	10.0		13	4.5		118	11.5		
4 years	71	5.4		7	2.4		64	6.3		
5 years	44	3.4		2	0.7		42	4.1		
6 years	36	2.7		0	0.0		36	3.5		
7 years	17	1.3		1	0.3		16	1.6		
8 years	10	0.8		0	0.0		10	1.0		
9 years	4	0.3		1	0.3		3	0.3		
10 years	6	0.5		1	0.3		5	0.5		
11 years	2	0.2		0	0.0		2	0.2		
17 years	1	0.1		0	0.0		1	0.1		
Missing	23			5			18			
<b>Certolizumab pegol</b>										<.0001
No	9501	99.4		3805	99.8		5696	99.1		
Yes	60	0.6		6	0.2		54	0.9		
Missing	645			226			446			
<b>Certolizumab: Estimated duration of treatment before entry in I-CARE (years)</b>										.
<1 year	35	59.3		2	33.3		33	62.3		
1 year	14	23.7		2	33.3		12	22.6		
2 years	4	6.8		0	0.0		4	7.5		
3 years	4	6.8		1	16.7		3	5.7		
4 years	1	1.7		0	0.0		1	1.9		
5 years	1	1.7		1	16.7		0	0.0		
Missing	1			0			1			
<b>Golimumab</b>										<.0001
No	9347	98.5		3700	97.1		5717	99.4		
Yes	141	1.5		109	2.9		32	0.6		

	Total N= 10207			Ulcerative colitis or IBD Unclassified N=4038 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
Missing	648			228			420			
<b>Golimumab: Estimated duration of treatment before entry in I-CARE (years)</b>										
<1 year	95	68.8		74	67.9		21	72.4		
1 year	25	18.1		22	20.2		3	10.3		
2 years	11	8.0		9	8.3		2	6.9		
3 years	6	4.3		4	3.7		2	6.9		
4 years	1	0.7		0	0.0		1	3.4		
Missing	3			0			3			
<b>Vedolizumab</b>										
No	9392	98.5		3753	98.9		5639	98.2		0.0030
Yes	147	1.5		41	1.1		106	1.8		
Missing	667			243			424			
<b>Vedolizumab: Estimated duration of treatment before entry in I-CARE (years)</b>										
<1 year	91	63.2		29	72.5		62	59.6		
1 year	32	22.2		6	15.0		26	25.0		
2 years	16	11.1		3	7.5		13	12.5		
3 years	4	2.8		2	5.0		2	1.9		
4 years	1	0.7		0	0.0		1	1.0		
Missing	2			1			1			
<b>Ustekinumab</b>										
No	9518	99.6		3807	99.9		5711	99.4		0.0002
Yes	38	0.4		4	0.1		34	0.6		
Missing	650			226			424			
<b>Ustekinumab: Estimated duration of treatment before entry in I-CARE (years)</b>										
<1 year	28	73.7		3	75.0		25	73.5		
1 year	4	10.5		0	0.0		4	11.8		
2 years	2	5.3		1	25.0		1	2.9		
3 years	1	2.6		0	0.0		1	2.9		
4 years	3	7.9		0	0.0		3	8.8		

\* Chi-square test

Abbreviation : SD (Standard Deviation)

**Supplementary Table 6. History of cancer**

	Total N= 10206			Ulcerative colitis or IBD Unclassified N=4037 (39.6%)			Crohn's Disease N=6169 (60.4%)			p*
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Personal history of cancer</b>										
No	9908	97.1		3902	96.7		6006	97.4		0.0395
Yes	298	2.9		135	3.3		163	2.6		
<b>DYSPLASIA Colon</b>										
No	10186	99.8		4026	99.7		6160	99.9		0.1574
Yes	20	0.2		11	0.3		9	0.1		
<b>DYSPLASIA Esophagus</b>										
No	10203	100.0		4037	100.0		6166	100.0		0.2827
Yes	3	0.0		0	0.0		3	0.0		
<b>DYSPLASIA Uterine cervix (only CIN 3)</b>										
No	10135	99.3		4003	99.2		6132	99.4		0.1496
Yes	71	0.7		34	0.8		37	0.6		
<b>DYSPLASIA Uterine cervix (only women)</b>										
No	5314	98.7		1998	98.3		3316	98.9		0.0756
Yes	71	1.3		34	1.7		37	1.1		

\* Chi-square test or Fisher's exact test  
Abbreviation : SD (Standard Deviation)



**Supplementary Table 7. History of vaccination and infection**

	Total			Ulcerative colitis or IBD Unclassified			Crohn's Disease			p*
	N= 10206			N=4037 (39.6%)			N=6169 (60.4%)			
	N	%/mean	SD	N	%/mean	SD	N	%/mean	SD	
<b>Human papilloma virus vaccine</b>										0.6856
No	6088	93.8		2443	94.0		3645	93.7		
Yes	404	6.2		158	6.0		246	6.3		
Missing	3714			1436			2278			
<b>Hepatitis B vaccine</b>										0.0379
No	2646	43.5		1093	45.1		1553	42.4		
Yes	3441	56.5		1331	54.9		2110	57.6		
Missing	4119			1613			2506			
<b>Pneumococcus vaccine</b>										<.0001
No	4031	64.9		1762	71.6		2269	60.5		
Yes	2184	35.1		700	28.4		1484	39.5		
Missing	3991			1575			2416			
<b>BCG vaccine</b>										0.4242
No	2609	46.1		1074	46.8		1535	45.7		
Yes	3046	53.9		1222	53.2		1824	54.3		
Missing	4551			1741			2810			
<b>Herpes zoster</b>										0.7668
No	5984	97.4		2426	97.5		3558	97.3		
Yes	160	2.6		63	2.5		97	2.7		
Missing	4062			1548			2514			
<b>Confirmed symptomatic mononucleosis</b>										0.2027
No	7178	95.0		2910	95.4		4268	94.8		
Yes	376	5.0		140	4.6		236	5.2		
Missing	2652			987			1665			

\* Chi-square test

Abbreviation : BCG (Bacille Calmette-Guerin), SD (Standard Deviation)

## What You Need to Know

**Background:** There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care.

**Findings:** I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients.

**Implications for patient care:** Future findings from I-CARE and sub-studies will likely be implemented in IBD guidelines and used to guide the decision-making process in daily practice.